

CITATION REPORT

List of articles citing

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

DOI: 10.1038/ng.449

Nature Genetics, 2009, 41, 1105-9.

Source: <https://exaly.com/paper-pdf/46336233/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2059	Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children. 2014 , 30, 519-24		2
2058	HCV innate immune responses. <i>Viruses</i> , 2009 , 1, 1073-88	6.2	4
2057	Genomics: Hepatitis C virus gets personal. 2009 , 461, 357-8		26
2056	Interferon-alfa, interferon-lambda and hepatitis C. <i>Nature Genetics</i> , 2009 , 41, 1048-50	36.3	60
2055	Notable advances. 2009 , 15, 1349-1349		
2054	A SNP for hepatitis C treatment failure. 2009 , 10, 739-739		
2053	Getting personal: the promises and pitfalls of personalized medicine. 2009 , 154, 269-71		6
2052	Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. 2010 , 5, 158-73		28
2051	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 2010 , 24, F23-9		163
2050	Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h. 2010 , 22, 1211-20		4
2049	Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. 2010 , 17, 550-7		9
2048	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. 2010 , 24, 2639-44		5
2047	Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. 2011 , 16, 141-7		38
2046	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. 2010 , 15, 881-6		28
2045	The Forefront of Treatment of Type B/C Chronic Hepatitis.. 2010 , 99, 3080-3086		
2044	Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. 2010 , 15, 1099-106		19
2043	?????????????. 2010 , 7, 24-25		

2042 ??????????????. **2010**, 7, 24-25

2041 2. Current Treatment and Future Prospects of Viral Hepatitis.. **2010**, 99, 499-505

2040 Interferon-induced gene expression in chronic hepatitis C. **2010**, 5, 25-31

2039 New direct-acting antivirals in the development for hepatitis C virus infection. **2010**, 3, 191-202 42

2038 Antitumor activity of type I and type III interferons in BNL hepatoma model. **2010**, 59, 1059-71 88

2037 Structure and function of interleukin-22 and other members of the interleukin-10 family. **2010**, 67, 2909-35 35

2036 IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. **2010**, 45, 903-10 41

2035 New antiviral therapies for chronic hepatitis C. **2010**, 4, 548-61 89

2034 Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. **2010**, 4, 723-31 12

2033 How the Human Genome Can Predict Response to Hepatitis C Therapy. **2010**, 9, 1-8 2

2032 Treatment uptake of patients with chronic hepatitis C: can we expect and do more?. **2010**, 55, 3300-3 4

2031 Viral hepatitis and HIV co-infection. **2010**, 85, 303-15 155

2030 Development of novel therapies for hepatitis C. **2010**, 86, 79-92 66

2029 IL28B polymorphisms and chronic hepatitis C. **2010**, 34, 587-9 11

2028 Individualized medicine 2010. **2010**, 14, 2257-63 1

2027 Snipping away at hepatitis C. **2010**, 51, 703-5 2

2026 The utility of genome-wide association studies in hepatology. **2010**, 51, 1833-42 32

2025 Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. **2010**, 51, 1904-11 101

2024	Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. 2010 , 52, 33-7	166
2023	Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. 2010 , 52, 421-9	219
2022	c-Jun NH(2)-terminal kinase 1 in hepatocytes: an essential mediator of insulin resistance. 2010 , 51, 2221-3	1
2021	Personalized medicine in hepatitis C: from genome-wide association studies to clinical practice. 2010 , 51, 2223-5	
2020	Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 2010 , 52, 822-32	190
2019	Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. 2010 , 52, 1216-24	140
2018	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. 2010 , 52, 1888-96	310
2017	Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2010 , 82, 1859-68	19.7 35
2016	Viral hepatitis: human genes that limit infection. 2010 , 24, 709-23	15
2015	Assessing the human immune system through blood transcriptomics. 2010 , 8, 84	178
2014	Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. 2010 , 3, 48	47
2013	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. <i>Liver International</i> , 2010 , 30, 1259-69	7.9 122
2012	The recent breakthroughs in the understanding of host genomics in hepatitis C. 2010 , 40, 950-9	24
2011	Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection. 2010 , 88, 708-11	7
2010	Hepatitis C: An unsuspected drug target. 2010 , 465, 42-4	6
2009	Materials science: Muscle mimic. 2010 , 465, 44-5	10
2008	Genome-wide association studies in pharmacogenomics. 2010 , 11, 241-6	209
2007	Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity?. 2010 , 1214, 18-33	129

2006 Polymorphisme de IL 28B et réponse au traitement anti-VHC. **2010**, 2010, 28

2005 Individualisation of antiviral therapy for chronic hepatitis C. **2010**, 25, 1206-16

16

2004 Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies. **2010**, 2, 73-82

3

2003 Predictors of response to chronic hepatitis C treatment. *Annals of Hepatology*, **2010**, 9, S54-S60

3.1 9

2002 Beyond Genetics-Stratified and Personalised Medicines Using Multiple Parameters. **2010**, 3, 1637-1651

3

2001 CoAIMs: a cost-effective panel of ancestry informative markers for determining continental origins. **2010**, 5, e13443

19

2000 Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. **2010**, 5, e9032

32

1999 IL28B SNP rs8099917 is strongly associated with pegylated interferon- α and ribavirin therapy treatment failure in HCV/HIV-1 coinfecting patients. **2010**, 5, e13771

64

1998 Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. **2010**, 5, e14132

22

1997 Safety, Tolerability, and Immunogenicity of Interferons. **2010**, 3, 1162-1186

17

1996 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. **2010**, 3, 133-45

3

1995 Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. **2010**, 202, 576-84

30

1994 Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. **2010**, 65, 2063-9

33

1993 Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. **2010**, 51, 1209-16

51

1992 Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. **2010**, 202, 1185-91

31

1991 Evolution of interferon-based therapy for chronic hepatitis C. **2010**, 2010, 140953

8

1990 Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. **2010**, 2010, 702748

4

1989 Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. **2010**, 201, 1663-71

27

1988	Genomic approaches to the study of HIV-1 acquisition. 2010 , 202 Suppl 3, S382-6		13
1987	Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. 2010 , 84, 9140-8		50
1986	Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 727-32	3.5	12
1985	Genome-wide association studies and genetic risk assessment of liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 669-81	24.2	61
1984	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. 2010 , 4, 63-79		7
1983	Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. 2010 , 207, 2703-17		213
1982	Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses. 2010 , 11, 1403-25		12
1981	Genomic scale analysis of racial impact on response to IFN-alpha. 2010 , 107, 803-8		14
1980	Interferon- λ in HCV Infection and Therapy. <i>Viruses</i> , 2010 , 2, 1589-602	6.2	27
1979	[Highlights in gastroenterology 2010]. 2010 , 99, 1399-411		
1978	A new insight into hepatitis C vaccine development. 2010 , 2010, 548280		32
1977	Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy. 2010 , 39, 598-610		3
1976	Antisense gets a grip on miR-122 in chimpanzees. 2010 , 2, 13ps1		12
1975	Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. 2010 , 2010, 703602		9
1974	[Hepatology 2010]. 2010 , 135, 1290-4		1
1973	[Predictive medicine - clinical genetics 2010]. 2010 , 135, 1334-8		0
1972	Fibrosis in the liver: acute protection and chronic disease. 2010 , 97, 151-200		25
1971	Translating genomics into improved healthcare. 2010 , 341, c5945		12

1970	[Genome-wide association studies in hepatology]. 2010 , 48, 56-64	4
1969	Pharmacogenetics of hepatitis C therapy. 2010 , 11, 135-9	4
1968	Management of untreated and nonresponder patients with chronic hepatitis C. 2010 , 30, 348-60	3
1967	New insights into structure and replication of the hepatitis C virus and clinical implications. 2010 , 30, 333-47	61
1966	Safety of small molecules in combination with interferon-based therapy for hepatitis C virus. 2010 , 9, 883-92	5
1965	Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfecting with HIV and hepatitis C virus. 2010 , 51, 788-95	128
1964	Resistance to direct antiviral agents in patients with hepatitis C virus infection. 2010 , 138, 447-62	442
1963	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. 2010 , 138, 1338-45, 1345.e1-7	956
1962	Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 2010 , 138, 2307-14	307
1961	Reaping the early harvest of the genomics revolution. 2010 , 138, 1653-4	2
1960	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. 2010 , 139, 499-509	352
1959	Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 2010 , 139, 1181-9	156
1958	ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. 2010 , 139, 1190-7	145
1957	A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. 2010 , 139, 1586-92, 1592.e1	265
1956	In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. 2010 , 139, 1422-4	16
1955	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. 2010 , 139, 1577-85, 1585.e1-3	179
1954	A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. 2010 , 139, 1794-6	14
1953	IL28B and the control of hepatitis C virus infection. 2010 , 139, 1865-76	191

1952	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. 2010 , 16, 277-86	56
1951	Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. 2010 , 52, 452-4	33
1950	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. 2010 , 53, 439-43	121
1949	Crystal structure of human interferon- β in complex with its high-affinity receptor interferon- β 1. 2010 , 404, 650-64	59
1948	Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. 2010 , 138, 1240-3	32
1947	Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C. 2010 , 40, 757-62	5
1946	lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. 2010 , 40, 449-60	38
1945	High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. 2010 , 40, 956-62	14
1944	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. 2010 , 40, 1155-67	20
1943	ITPA gene variant protects against anemia induced by pegylated interferon- β and ribavirin therapy for Japanese patients with chronic hepatitis C. 2010 , 40, 1063-71	58
1942	An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 2010 , 139, 821-7, 827.e1	259
1941	Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 2010 , 139, 120-9.e18	582
1940	Uncovering the roles of rare variants in common disease through whole-genome sequencing. 2010 , 11, 415-25	1082
1939	What have we learned from the IL28 receptor knockout mouse?. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 579-84	3.5 22
1938	Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. 2010 , 8, 497-9	14
1937	Pharmacogenetics and human genetic polymorphisms. 2010 , 429, 435-49	78
1936	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. 2010 , 116, 2875-83	65
1935	Management of nonresponsive hepatitis C. 2010 , 8, 379-95	3

1934	Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 585-90	3.5	34
1933	Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 485-94	24.2	54
1932	IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 2011 , 106, 38-45		68
1931	Tailor-made therapy for viral hepatitis: recent advances. 2011 , 84 Suppl 1, 1-4		2
1930	Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. 2011 , 3, 8		10
1929	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. 2011 , 11, 301-13		13
1928	Treatment of acute HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 265-74	24.2	43
1927	Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 285-95	24.2	24
1926	Interferon lambdas: the next cytokine storm. 2011 , 60, 1284-93		89
1925	IL28B-genotype testing now and in the era of direct-acting antiviral agents. 2011 , 9, 293-4		11
1924	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. 2011 , 9, 535-43		16
1923	Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. 2011 , 141, 1656-64		35
1922	Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. 2011 , 15, 497-513		13
1921	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. 2011 , 60, 261-7		87
1920	Mechanisms of non-response to antiviral treatment in chronic hepatitis C. 2011 , 35 Suppl 1, S31-41		17
1919	Direct-acting antiviral (DAA) actions in treatment-naïve patients. 2011 , 35 Suppl 2, S52-8		2
1918	Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. 2011 , 140, 1021-31		212
1917	Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. 2011 , 140, 1314-21		103

1916	A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. 2011 , 141, 320-5, 325.e1-2	62
1915	Has genetics eradicated the good old predictors of hepatitis C treatment response?. 2011 , 35, 157-8	2
1914	Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. 2011 , 38, 538-9	7
1913	Resistance to anti-HCV protease inhibitors. 2011 , 1, 599-606	35
1912	Inborn errors of anti-viral interferon immunity in humans. 2011 , 1, 487-96	98
1911	Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. 2011 , 1, 497-512	95
1910	Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. 2011 , 1, 590-8	89
1909	IL28B: A new wager in the skyline of hepatitis C virus infection. 2011 , 43, 177-9	6
1908	Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. 2011 , 43, 850-5	13
1907	Host genetics in immune-mediated hepatitis C virus clearance. 2011 , 5, 155-69	17
1906	CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C. 2011 , 46, 973-80	2
1905	Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?. 2011 , 33, 744-50	2
1904	Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. 2011 , 14, 1068-77	48
1903	Vaccination for hepatitis C virus: closing in on an evasive target. 2011 , 10, 659-72	86
1902	Genome-wide association studies and susceptibility to infectious diseases. 2011 , 10, 98-107	48
1901	The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. 2011 , 92, 2227-2236	20
1900	Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. 2011 , 13, 446-51	19
1899	Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. 2011 , 140, 1961-9	48

1898	High-dose pegylated interferon- β and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). 2011 , 141, 119-27		25
1897	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. 2011 , 141, 128-40, 140.e1-2		37
1896	Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment. 2011 , 84 Suppl 1, 50-5		2
1895	A new standard of care for the treatment of chronic HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 257-64	24.2	104
1894	Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. 2011 , 106, 1246-54		28
1893	Integrative genomics strategies to elucidate the complexity of drug response. 2011 , 12, 1695-715		25
1892	IL-29 and IFN β differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFN γ receptor expression. 2011 , 117, 2385-95		67
1891	IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. 2011 , 92, 1071-1081		46
1890	Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. 2011 , 9, 344-350.e2		147
1889	1990-2010: two decades of interferon-based therapy. 2011 , 15, 473-82		8
1888	Interferons as therapeutic agents for infectious diseases. 2011 , 25, 819-34		20
1887	Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymorphisms in hepatitis C virus (HCV) infection. 2011 , 49, 1247-1256		16
1886	Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. 2011 , 84 Suppl 1, 56-61		5
1885	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. 2011 , 3, 57		57
1884	Biotherapeutic bioanalysis: a multi-indication case study review. 2011 , 3, 623-43		19
1883	IFN- β . 2011 , 23, 583-90		174
1882	[Genetics and hepatitis C treatment: towards a personalized treatment?]. 2011 , 34, 352-60		3
1881	IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. <i>Liver International</i> , 2012 , 32, 476-86	7.9	34

1880	Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. 2011 , 52, 363-6	39
1879	Interferon-lambda and therapy for chronic hepatitis C virus infection. 2011 , 32, 443-50	55
1878	Mixing the right hepatitis C inhibitor cocktail. 2011 , 17, 34-46	31
1877	The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. 2011 , 54, 219-26	21
1876	IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. 2011 , 54, 716-22	146
1875	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. 2011 , 54, 408-14	70
1874	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. 2011 , 54, 439-48	104
1873	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. 2011 , 54, 415-21	186
1872	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. 2011 , 54, 604-11	41
1871	Interferon-lambda serum levels in hepatitis C. 2011 , 54, 859-65	118
1870	Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. 2011 , 54, 866-71	64
1869	Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. 2011 , 54, 887-93	191
1868	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. 2011 , 54, 1094-101	81
1867	Insights into the role of interferon lambda in hepatitis C virus infection. 2011 , 54, 844-7	6
1866	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. 2011 , 55, 69-75	137
1865	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. 2011 , 55, 76-85	49
1864	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. 2011 , 55, 322-7	108
1863	IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. 2011 , 55, 289-98	111

1862	Viral genotype-specific role of PNPLA3, PPARG, MTP, and IL28B in hepatitis C virus-associated steatosis. 2011 , 55, 529-535	89
1861	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. 2011 , 55, 980-8	92
1860	EASL Clinical Practice Guidelines: management of hepatitis C virus infection. 2011 , 55, 245-64	983
1859	IL28B single nucleotide polymorphisms in the treatment of hepatitis C. 2011 , 55, 692-701	86
1858	The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5B2 mutation. 2011 , 55, 1201-6	20
1857	[IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs]. 2011 , 32, 271-4	0
1856	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. 2011 , 49, 1853-60	60
1855	Induction and function of type I and III interferon in response to viral infection. 2011 , 1, 476-86	204
1854	Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. 2011 , 41, 126-32	2
1853	Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads. 2011 , 41, 626-34	2
1852	Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance. 2011 , 41, 722-30	2
1851	Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy. 2011 , 41, 904-9	2
1850	Cholesterol and chronic hepatitis C virus infection. 2011 , 41, 697-710	14
1849	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. 2011 , 41, 1126-31	2
1848	Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients. 2011 , 41, 1153-68	8
1847	Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. 2011 , 41, 1137-44	11
1846	Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. 2011 , 41, 1216-22	6
1845	Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy. 2011 , 41, 1145-52	8

1844	Favorable factors for re-treatment with pegylated interferon β 2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. 2011 , 41, 1169-77		4
1843	Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma. <i>Liver International</i> , 2011 , 31, 1006-12	7.9	18
1842	Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. 2011 , 90, 712-21		14
1841	Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making. 2011 , 1, 27-33		3
1840	[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1]. 2011 , 29 Suppl 5, 51-8		3
1839	Increasing burden of liver disease in patients with HIV infection. 2011 , 377, 1198-209		215
1838	Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. 2011 , 17, 70-8		13
1837	Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C. 2011 , 3, CMT.S4015		0
1836	Individualization of antiretroviral therapy. 2012 , 5, 1-17		11
1835	Potential role of interferon-lambda in the treatment of inflammation and cancer: an update. 2011 , 51		
1834	Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011 , 10, 452-457	3.1	20
1833	Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy. 2011 , 2, 715-718		1
1832	Clinical application of high throughput molecular screening techniques for pharmacogenomics. 2011 , 4, 109-21		8
1831	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C. 2011 , 139, 704-709		
1830	Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. 2011 , 16, 1073-80		28
1829	IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. 2011 , 6, e18322		68
1828	Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). 2011 , 6, e21284		20
1827	An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers. 2011 , 6, e21997		10

1826	USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon β response. 2011 , 6, e22200	174
1825	Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. 2011 , 6, e23856	12
1824	IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfecting persons undergoing peginterferon and ribavirin therapy. 2011 , 6, e25753	19
1823	Genetic variation of the IL-28B promoter affecting gene expression. 2011 , 6, e26620	39
1822	Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection. 2011 , 6, e27223	9
1821	Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. 2011 , 6, e27555	71
1820	Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. 2011 , 6, e28617	22
1819	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. 2011 , 16, 685-94	34
1818	Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon- β 2b plus ribavirin. 2011 , 16, 1081-91	25
1817	Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. 2011 , 21, 289-96	29
1816	A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. 2011 , 23, 931-5	32
1815	Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 2011 , 25, 269-71	23
1814	IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfecting patients treated with pegylated interferon and ribavirin. 2011 , 25, 1025-33	35
1813	Host genetics. 2011 , 6, 491-500	4
1812	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfecting patients with prior nonresponse or relapse. 2011 , 25, 1131-3	20
1811	Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon β -2b and ribavirin. 2011 , 23, 177-83	7
1810	Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. 2011 , 25, F21-7	121
1809	Update on hepatitis C virus-specific immunity. 2011 , 6, 559-65	8

1808	Genetics in liver disease: new concepts. 2011 , 27, 231-9	15
1807	What did we learn on host's genetics by studying large cohorts of HIV-1-infected patients in the genome-wide association era?. 2011 , 6, 290-6	5
1806	HIV-1 decreases the levels of neurotrophins in human lymphocytes. 2011 , 25, 1126-8	22
1805	[Current status of researches in genomic medicine and the guidelines for pharmacogenomics (PGx)]. 2011 , 131, 263-8	
1804	Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C. 2011 , 115, 263-9	10
1803	Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection. 2012 , 5, 525-8	3
1802	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. 2012 , 17, 111-8	8
1801	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. 2011 , 16, 227-35	5
1800	Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon- α -2a therapy. 2011 , 16, 629-37	71
1799	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. 2011 , 50, 2083-8	13
1798	Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. 2011 , 50, 2731-6	6
1797	Cytokine (IL-10, IL-28B and LT-A) gene polymorphisms in chronic hepatitis C virus infection. 2011 , 5, 9-19	10
1796	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. 2012 , 17, 35-43	9
1795	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. 2012 , 17, 477-84	38
1794	Pegylated interferon- α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. 2011 , 16, 979-88	10
1793	Genome-wide association studies of asthma. 2011 , 60, 247-52	15
1792	Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. 2012 , 17, 571-5	13
1791	Personalized medicine - the promised land: are we there yet?. 2011 , 79, 403-12	25

1790	Hepatitis C virus: How genetic variability affects pathobiology of disease. 2011 , 26 Suppl 1, 83-95	51
1789	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. 2011 , 26, 1374-9	28
1788	Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. 2011 , 26, 1089-105	115
1787	Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. 2011 , 26, 1348-53	6
1786	Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. 2011 , 55, 418-26	16
1785	IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 2011 , 33, 1162-72	77
1784	Meta-analysis: insulin resistance and sustained virological response in hepatitis C. 2011 , 34, 297-305	82
1783	Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. 2011 , 154, 659-61	6
1782	Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. 2011 , 18, 280-6	21
1781	Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon β plus ribavirin therapy. 2011 , 18, 349-57	6
1780	Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. 2011 , 18, e66-74	36
1779	Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 2011 , 18, e134-43	24
1778	A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. 2011 , 18, e270-7	10
1777	IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. 2011 , 18, e325-31	43
1776	Hepatitis C virus replication in Caucasian HIV controllers. 2011 , 18, e350-7	24
1775	IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. 2011 , 18, e550-60	5
1774	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. 2011 , 12, 487-93	15
1773	Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. <i>Liver International</i> , 2011 , 31, 36-41	7.9 9

1772	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , 2011 , 31 Suppl 1, 36-44	7.9	8
1771	Future hepatitis C virus treatment: interferon-sparing combinations. <i>Liver International</i> , 2011 , 31 Suppl 1, 62-7	7.9	31
1770	Hepatitis C virus genotype 4 therapy: progress and challenges. <i>Liver International</i> , 2011 , 31 Suppl 1, 45-52.	7.9	44
1769	The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. <i>Liver International</i> , 2011 , 31 Suppl 1, 29-35	7.9	25
1768	How to use virological tools for the optimal management of chronic hepatitis C. <i>Liver International</i> , 2011 , 31 Suppl 1, 3-12	7.9	19
1767	Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. <i>Liver International</i> , 2011 , 31, 443-60	7.9	44
1766	Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. <i>Liver International</i> , 2011 , 31, 1118-26	7.9	58
1765	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. <i>Liver International</i> , 2011 , 31, 1359-65	7.9	24
1764	Genetics of liver injury and fibrosis. 2011 , 35, 800-3		5
1763	Virological tools to diagnose and monitor hepatitis C virus infection. 2011 , 17, 116-21		45
1762	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. <i>Nature Genetics</i> , 2011 , 43, 455-8	36.3	296
1761	IL28B genetic variations are associated with high sustained virological response (SVR) of interferon- β plus ribavirin therapy in Taiwanese chronic HCV infection. <i>Genes and Immunity</i> , 2011 , 12, 300-9	4.4	41
1760	Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. 2011 , 11, 1051-7		71
1759	The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. 2011 , 11, 1325-9		6
1758	IL28B polymorphisms are not associated with the response to interferon- β in multiple sclerosis. 2011 , 239, 101-4		16
1757	Real-time polymerase chain reaction assay based on high-resolution melting analysis for the determination of the rs12979860 polymorphism involved in hepatitis C treatment response. 2011 , 175, 125-8		7
1756	Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. 2011 , 178, 235-8		8
1755	The use of genomic information to optimize cancer chemotherapy. 2011 , 38, 186-95		19

1754	Pharmacogenetics: past, present and future. 2011 , 16, 852-61	61
1753	A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. 2011 , 16, 884-90	18
1752	Regulation and functions of the IL-10 family of cytokines in inflammation and disease. 2011 , 29, 71-109	1132
1751	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. 2011 , 204, 84-93	109
1750	Liver interleukin-8 messenger RNA expression and interferon sensitivity-determining region mutations relate to treatment response in hepatitis C 1b. 2011 , 16, 825-32	6
1749	Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. 2011 , 12, 1729-40	14
1748	Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. 2011 , 46, 955-61	30
1747	Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. 2011 , 203, 1748-52	42
1746	Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype. 2011 , 53, 1410-1	7
1745	Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. 2011 , 56, 3335-42	23
1744	Ultra-rapid virological response, young age, low EGT/ALT -ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN- α (2a) monotherapy. 2011 , 56, 3296-304	6
1743	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. 2011 , 46, 401-9	31
1742	The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. 2011 , 46, 944-52	16
1741	A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. 2011 , 46, 1010-9	20
1740	Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. 2011 , 46, 1031-7	12
1739	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. 2011 , 46, 929-37	28
1738	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. 2011 , 5, 789-99	10
1737	A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin. 2011 , 4, 255-261	2

1736	Individualisierte Medizin 2011. 2011 , 6, 106-111		1
1735	The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. 2011 , 13, 78-86		17
1734	IL28B Polymorphisms and Treatment of Hepatitis C. 2011 , 10, 70-78		
1733	HCV and HIV Coinfection. 2011 , 10, 52-61		1
1732	IL28B: Implications for Therapy. 2011 , 10, 153-161		
1731	Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. 2011 , 10, 214-227		46
1730	Hepatitis C Virus and Innate Immunity: Taking a Fresh Look into an Old Issue. 2011 , 10, 186-195		
1729	Treatment of Chronic Hepatitis C in the Age of Direct-Acting Antivirals with Emphasis on First Generation Inhibitors of HCV NS3/4A Protease. 2011 , 10, 204-213		
1728	Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. 2011 , 11, 177		18
1727	Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. 2011 , 11, 10		3
1726	Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial. 2011 , 4, 220		1
1725	Transforming growth factor β polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus-induced liver disease. 2011 , 17, 279-88		20
1724	Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. 2011 , 17, 289-98		57
1723	Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes?. 2011 , 17, 219-21		5
1722	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. <i>Journal of Medical Virology</i> , 2011 , 83, 419-27	19.7	5
1721	Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 437-44	19.7	12
1720	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. <i>Journal of Medical Virology</i> , 2011 , 83, 445-52	19.7	19
1719	Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2011 , 83, 981-8	19.7	9

1718	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. <i>Journal of Medical Virology</i> , 2011 , 83, 871-8	19.7	43
1717	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 1048-57	19.7	41
1716	Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2011 , 83, 1203-11	19.7	6
1715	Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 1016-22	19.7	46
1714	Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. <i>Journal of Medical Virology</i> , 2011 , 83, 1559-64	19.7	1
1713	Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. <i>Journal of Medical Virology</i> , 2011 , 83, 1597-607	19.7	27
1712	Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?. 2011 , 53, 715-6		6
1711	The complexity of fatigue. 2011 , 53, 717-8		1
1710	Serum lipid profile and chronic hepatitis C virus. 2011 , 53, 716-7		
1709	No evidence for caspase-dependent apoptosis in acetaminophen hepatotoxicity. 2011 , 53, 718-9		34
1708	Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. 2011 , 53, 7-13		155
1707	Beta-blockers in patients with cirrhosis and refractory ascites. 2011 , 53, 1783		6
1706	Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy. 2011 , 53, 1409-10		4
1705	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. 2011 , 53, 1411-2		4
1704	Hepatitis C pharmacogenetics: state of the art in 2010. 2011 , 53, 336-45		120
1703	Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections. 2011 , 53, 1412-3		21
1702	Quantitation of pretreatment serum interferon- γ -inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. 2011 , 53, 14-22		86
1701	Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. 2011 , 53, 415-21		84

1700	Depression and antiviral response to interferon-based therapy for hepatitis C virus infection. 2011 , 53, 1413-4	2
1699	Need for a three-focused approach to nonalcoholic fatty liver disease. 2011 , 53, 1773; author reply 1774	8
1698	Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. 2011 , 53, 317-24	182
1697	Pathogen DNA also contributes to interferon regulatory factor 3 activation in hepatic cells: Implications for alcoholic liver diseases. 2011 , 53, 1783-4	1
1696	Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. 2011 , 53, 1784	24
1695	Does the donor mannose-binding lectin genotype really predict the risk of bacterial infections after liver transplantation?. 2011 , 53, 1786-7	6
1694	Insulin resistance links nonalcoholic fatty liver to cardiovascular diseases. 2011 , 53, 1785-6	2
1693	Hyponatremia in patients with acute variceal bleeding treated with terlipressin. 2011 , 53, 714; author reply 714-5	5
1692	The importance of the definition of early virological response for predicting treatment efficacy for chronic hepatitis C. 2011 , 53, 1403; author reply 1403	2
1691	Reply. 2011 , 53, 1774-1774	
1690	Is endotoxemia a therapeutic target in liver injury?. 2011 , 53, 1785	1
1689	IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. 2011 , 53, 746-54	107
1688	Reply. 2011 , 53, 714-715	
1687	Insulin sensitizers in nonalcoholic steatohepatitis. 2011 , 53, 1404-5; author reply 1405	4
1686	"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. 2011 , 53, 1405-6; author reply 1407	2
1685	Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. 2011 , 53, 1399; author reply 1400	4
1684	Warning: Genome-wide association studies can be misleading. An example in hepatology. 2011 , 53, 1408; author reply 1408-9	3
1683	Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. 2011 , 53, 1400-1; author reply 1402	9

- 1682 Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. **2011**, 53, 1774-5; author reply 1775-6 1
- 1681 Reply:. **2011**, 53, 1400-1400
- 1680 Correspondence. **2011**, 53, 1403-1403
- 1679 Reply:. **2011**, 53, 1402-1402 0
- 1678 Reply:. **2011**, 53, 1405-1405 6
- 1677 The impact of human immunodeficiency virus infection in liver transplantation for hepatocellular carcinoma. **2011**, 53, 1777-8; author reply 1778-9 2
- 1676 Reply:. **2011**, 53, 1407-1407
- 1675 Reply:. **2011**, 53, 1408-1409
- 1674 Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. **2011**, 53, 1776; author reply 1777 42
- 1673 Noninvasive assessment of cystic fibrosis-associated liver disease with acoustic radiation force impulse imaging. **2011**, 53, 1779-80; author reply 1780-1 9
- 1672 Reply. **2011**, 53, 1775-1776
- 1671 Detection of acetaminophen-cysteine adducts in cases of indeterminate liver failure is not diagnostic of intentional overdose. **2011**, 54, 746-7
- 1670 Reply. **2011**, 53, 1778-1779
- 1669 Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C. **2011**, 53, 1777-1777 5
- 1668 Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure. **2011**, 54, 747-8 3
- 1667 Noninvasive assessment of liver fibrosis: the need for better validation. **2011**, 53, 1781-2; author reply 1782-3 9
- 1666 Methods and interest of noninvasive assessment of liver fibrosis are still in debate. **2011**, 53, 1781; author reply 1782-3 4
- 1665 Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable?. **2011**, 54, 748 8

- 1664 Reply: The utility of noninvasive imaging in cystic fibrosis liver disease. **2011**, 53, 1780-1781
- 1663 Reply. **2011**, 53, 1782-1783
- 1662 Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. **2011**, 54, 749 8
- 1661 Liver biopsy interpretation in liver cancer. **2011**, 54, 750
- 1660 No transfats. **2011**, 54, 750-1 1
- 1659 Hepatocellular carcinoma and gene profiling: back from perspective to reality. **2011**, 54, 738; author reply 738-9 3
- 1658 Apply sound scientific methodology to the evaluation of new medical treatments. **2011**, 54, 739; author reply 740 1
- 1657 The ethics of placebo treatment for patients with acute exacerbation of chronic hepatitis B. **2011**, 54, 740; author reply 741-2
- 1656 Mechanisms by which TLR4 and endotoxin promote hepatocellular carcinoma require further investigation. **2011**, 54, 745; author reply 745-6 1
- 1655 Hepatitis C virus therapeutics: editing enzymes promising therapeutic targets?. **2011**, 54, 742; author reply 742-3
- 1654 Bacterial translocation attenuates the systemic hemodynamic improvement produced by terlipressin in patients with cirrhosis. **2011**, 54, 743-4; author reply 744 2
- 1653 Reply. **2011**, 54, 738-739
- 1652 Reply. **2011**, 54, 740-740
- 1651 Reply. **2011**, 54, 741-742
- 1650 Reply. **2011**, 54, 744-744
- 1649 Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. **2011**, 54, 764-71 31
- 1648 Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. **2011**, 54, 772-80 54
- 1647 Reply. **2011**, 54, 742-743

1646 Reply. **2011**, 54, 745-746

1645 Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. **2011**, 54, 1127-34 105

1644 An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. **2011**, 54, 1433-44 854

1643 Drug therapy: telaprevir. **2011**, 54, 1463-9 4

1642 Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. **2011**, 25, 269-80 31

1641 Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. **2011**, 11, 382-90 8

1640 Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production. **2011**, 11, 543-56 36

1639 IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. **2011**, 5, 461-78 4

1638 Interferon combination therapy for HIV/hepatitis C virus coinfection. **2011**, 3, 1087-102 1

1637 New insights into the HCV quasispecies and compartmentalization. **2011**, 31, 356-74 77

1636 The impact of human gene polymorphisms on HCV infection and disease outcome. **2011**, 31, 375-86 18

1635 Impact of IL-28B polymorphism on outcome in patients with hepatitis C after liver transplantation. **2011**, 5, 429-31 3

1634 Understanding the host genetics of chronic hepatitis B and C. **2011**, 31, 115-27 70

1633 [Genome-wide association studies]. **2011**, 136, 95-8 5

1632 Biomarkers that reflect immune activation or dysfunction will be important in the management of infectious diseases. **2011**, 5, 109-12 1

1631 IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. *Journal of Interferon and Cytokine Research*, **2011**, 31, 331-6 3,5 21

1630 Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. **2011**, 57, 48-56 61

1629 Personalized hepatitis C therapy: opportunities and pitfalls. **2011**, 11, 127-9 1

1628	Gastrointestinal and liver diseases: genetic and epigenetic markers. 2011 , 60, 1630-4	2
1627	Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 2011 , 203, 1629-36	55
1626	Genome-wide association study identified ITPA/DDRKG1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. 2011 , 20, 3507-16	75
1625	Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT. 2011 , 2011, 713216	11
1624	NK cells, innate immunity and hepatitis C infection after liver transplantation. 2011 , 52, 369-77	21
1623	Double-Filtration Plasmapheresis plus Interferon- α for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy. 2011 , 84 Suppl 1, 10-6	3
1622	The impact of genetic variability on liver disease in the Hispanic/Latin-American population. 2011 , 44, 549-54	1
1621	Genetics of infectious diseases: hidden etiologies and common pathways. 2011 , 49, 1427-37	10
1620	Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients. 2011 , 49, 2706-10	20
1619	Infections and the liver. 2011 , 29, 184-90	2
1618	High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. 2011 , 25, 1128-31	31
1617	Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. 2011 , 25, 1123-6	17
1616	TAP-independent human histocompatibility complex-Cw1 antigen processing of an HIV envelope protein conserved peptide. 2011 , 25, 265-9	5
1615	Pharmacogenomics: playing the odds. 2011 , 474, S9-10	57
1614	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. 2011 , 25, 761-6	23
1613	Pharmacodynamics of PEG-IFN- α -2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. 2011 , 56, 95-9	24
1612	Genomics and drug response. 2011 , 364, 1144-53	455
1611	Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. 2011 , 85, 5961-9	16

1610	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. 2011 , 108, 3719-24			54
1609	Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. 2011 , 108, 5736-41			106
1608	Impact of HCV genetic differences on pathobiology of disease. 2011 , 9, 747-59			31
1607	Factors affecting the effective number of tests in genetic association studies: a comparative study of three PCA-based methods. 2011 , 56, 428-35			4
1606	Evolutionary genetic dissection of human interferons. 2011 , 208, 2747-59			118
1605	Characteristics of highly polymorphic segmental copy-number variations observed in Japanese by BAC-array-CGH. 2011 , 2011, 820472			2
1604	Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. 2011 , 203, 595-601			50
1603	Interferon lambda: a new sword in cancer immunotherapy. 2011 , 2011, 349575			56
1602	Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. <i>Viruses</i> , 2012 , 4, 1264-78	6.2		20
1601	Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. <i>Hepatitis Monthly</i> , 2012 , 12, 77-84	1.8		9
1600	RHOA is a modulator of the cholesterol-lowering effects of statin. 2012 , 8, e1003058			24
1599	Comment on: Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection. 2012 , 51, 2300-2; author reply 2302			5
1598	Hepatitis C virus clearance after discontinuation of pegylated interferon alpha-2a monotherapy in a child. 2012 , 2012, 597348			0
1597	Copy-number variations observed in a Japanese population by BAC array CGH: summary of relatively rare CNVs. 2012 , 2012, 789024			
1596	The reduced predictive value of interleukin 28b gene polymorphisms in a cohort of patients with thyroiditis developed during antiviral therapy for chronic hepatitis C: a preliminary study. <i>Hepatitis Monthly</i> , 2012 , 12, e6036	1.8		
1595	Real response to therapy in chronic hepatitis C virus patients: a study from iran. <i>Hepatitis Monthly</i> , 2012 , 12, e6151	1.8		23
1594	[Therapy of chronic hepatitis B and C virus infections in the clinical practice]. 2012 , 101, 37-42			
1593	The Correlation of IL28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2012 , 11, 975-979	1.8		1

1592	Pharmacogenomics and patient care: one size does not fit all. 2012 , 4, 153ps18		39
1591	IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2011 , 11, 958-9	1.8	13
1590	Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. <i>Hepatitis Monthly</i> , 2012 , 12, e8387	1.8	29
1589	The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. 2012 , 2012, 849373		19
1588	dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. <i>Viruses</i> , 2012 , 4, 2598-635	6.2	115
1587	HIV and Liver Disease. 2012 ,		
1586	New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. 2012 , 156, 279-90		155
1585	HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment. 2012 , 7, 339-44		17
1584	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. 2012 , 34, 722-8		30
1583	Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. 2012 , 67, 1080-7		11
1582	HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypes. 2012 , 19, 223-7		8
1581	Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. 2012 , 5, 139-51		22
1580	[Personalised hepatology - current concepts, developments and expectations in the post-genome era]. 2012 , 50, 41-6		2
1579	[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. 2012 , 50, 57-72		38
1578	Management and treatment of chronic hepatitis C in HIV patients. 2012 , 32, 138-46		21
1577	Interferons as biomarkers and effectors: lessons learned from animal models. 2012 , 6, 159-76		9
1576	Telaprevir for the treatment of hepatitis C. 2012 , 13, 593-606		14
1575	Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. 2012 , 13, 847-9		7

1574	Retreatment with peginterferon α -2a + ribavirin in patients who failed previous peginterferon α -2b + ribavirin combination therapy. 2012 , 30, 554-60		2
1573	New challenges in viral hepatitis. 2012 , 61 Suppl 1, i1-5		20
1572	IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. 2012 , 28, 215-9		22
1571	Association between IL28B gene polymorphisms and sustained virological response in patients coinfecting with HCV and HIV in Brazil. 2012 , 67, 509-10		6
1570	Genomic variation-guided management in chronic hepatitis C. 2012 , 6, 497-506		8
1569	Allele-specific PCR for determination of IL28B genotype. 2012 , 50, 4144-6		7
1568	The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells. 2012 , 56, 903-8		6
1567	Plasma IL-6 and IL-9 predict the failure of interferon- α plus ribavirin therapy in HIV/HCV-coinfecting patients. 2012 , 67, 1238-45		27
1566	Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. <i>Hepatitis Monthly</i> , 2012 , 12, 190-5	1.8	28
1565	New perspectives in the therapy of chronic hepatitis B. 2012 , 61 Suppl 1, i18-24		45
1564	Achievement of sustained viral response after switching treatment from pegylated interferon α -2b to α -2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report. 2012 , 55, 306-10		2
1563	Genetically associated CD16(+)/56(-) natural killer cell interferon (IFN)- α expression regulates signaling and is implicated in IFN- α -induced hepatitis C virus decline. 2012 , 205, 1131-41		8
1562	Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. 2012 , 2012, 264017		11
1561	Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome. 2012 , 2012, 1-10		4
1560	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. 2012 , 55, 417-25		15
1559	Silencing of microRNA-122 enhances interferon- α signaling in the liver through regulating SOCS3 promoter methylation. 2012 , 2, 637		61
1558	Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. 2012 , 86, 1382-93		76
1557	Pharmacogenetics of hepatitis C. 2012 , 67, 523-9		26

1556	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 2012 , 34, 165-70		37
1555	The impact of host factors on management of hepatitis C virus. <i>Hepatitis Monthly</i> , 2012 , 12, 235-41	1.8	2
1554	Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFN α -2a. 2012 , 30, 561-7		2
1553	The adjuvant role of thyroxine in the treatment of chronic hepatitis C infection. 2012 , 105, 683-7		1
1552	Individualized Therapy for Chronic Hepatitis C. 2012 , 373-394		
1551	Hepatitis C and Hepatocellular Carcinoma: Implications for Pathogenesis and Treatment. 2012 , 143-203		
1550	Identification of novel HCV deletion mutants in chronic hepatitis C patients. 2012 , 17, 1551-61		1
1549	Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. 2012 , 17, 1453-8		11
1548	Dendritic Cells in Hepatitis Virus Infection: A Legatus Within. 2012 , 8, 12-22		
1547	Ethnic variability in the allelic distribution of pharmacogenes between Korean and other populations. 2012 , 22, 829-36		9
1546	Differences in virological response to peginterferon- α plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. 2012 , 60, 117-23		12
1545	Human capital contracts for global health: a plan to increase the number of physicians in resource limited settings. 2012 , 26, 1979-80		2
1544	Future perspectives: towards interferon-free regimens for HCV. 2012 , 17, 1201-10		15
1543	Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection. 2012 , 26, 1974-7		
1542	Racial differences in fibrosis progression after HCV-related liver transplantation. 2012 , 94, 178-84		11
1541	The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. 2012 , 94, 197-203		44
1540	Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. 2012 , 94, 275-80		21
1539	Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors. 2012 , 24, 1110-2		10

1538	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. 2012 , 17, 1059-67	21
1537	Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. 2012 , 17, 1163-70	7
1536	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 2012 , 17, 823-31	28
1535	Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. 2012 , 3, 200-206	12
1534	HCV genotype 5: an orphan virus. 2013 , 18, 263-9	3
1533	Molecular surveillance of hepatitis C. 2012 , 17, 1465-70	14
1532	Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. 2012 , 7, e29370	30
1531	Next-generation sequencing: application in liver cancer-past, present and future?. 2012 , 1, 383-94	15
1530	Direct-acting antiviral agents for the treatment of HCV. 2012 , 17, 1105-7	3
1529	[109th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 7. Cutting edge of the treatment for viral hepatitis]. 2012 , 101, 2681-9	
1528	A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2. 2012 , 51, 9-15	3
1527	A case of chronic hepatitis C with nephrotic diabetic nephropathy who achieved sustained viral remission by double-filtration plasmapheresis and interferon combination therapy. 2012 , 51, 1991-5	0
1526	Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfecting patients: a randomized international trial. 2012 , 13, 142-52	59
1525	Predictors of response to chronic hepatitis C treatment. 2012 , 7, 1089-1101	7
1524	Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfecting patients. 2012 , 13, 70-82	10
1523	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. 2012 , 26, 1977-9	8
1522	Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon- α and ribavirin therapy in hepatitis C virus/HIV-1-coinfecting patients. 2012 , 26, 1973-4	3
1521	Interferon-stimulated gene pathways in the treatment of viral hepatitis. 2012 , 7, 361-369	3

1520	HCV protease inhibitors: using the evidence to guide clinical practice. 2012 , 2, 923-937	2
1519	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 2012 , 97, 679-86	41
1518	Hepatitis C. 2012 , 564-598	2
1517	Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. 2012 , 19, 677-84	30
1516	Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. 2012 , 21, 111-8	6
1515	IFN- β inhibits HIV infection of macrophages through the JAK-STAT pathway. 2012 , 7, e35902	61
1514	IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. 2012 , 56, 2060-70	102
1513	Pharmacogenomics in clinical practice and drug development. 2012 , 30, 1117-24	80
1512	Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. 2012 , 19, 608-14	22
1511	An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. 2012 , 19, 615-22	19
1510	Anti-interferon- β neutralizing antibody is associated with nonresponse to pegylated interferon- β plus ribavirin in chronic hepatitis C. 2012 , 19, 694-703	21
1509	Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. 2012 , 19, 650-3	9
1508	Abstracts of the Australian Gastroenterology Week 2012. October 16-19, 2012. Adelaide, South Australia, Australia. 2012 , 27 Suppl 4, 2-189	
1507	Motility/Neurogastroenterology. 2012 , 27, 150-157	
1506	Paediatrics. 2012 , 27, 158-160	0
1505	Viral Hepatitis. 2012 , 27, 161-182	2
1504	Basic Science Luminal. 2012 , 27, 17-29	
1503	Endoscopy Lower. 2012 , 27, 30-49	

1502 Endoscopy Upper. **2012**, 27, 50-67

1501 Hepatology Clinical. **2012**, 27, 68-95

1500 IBD Clinical. **2012**, 27, 96-122

1499 Luminal Clinical. **2012**, 27, 123-138

1498 Nutrition Basic Science. **2012**, 27, 139-139

1497 Nutrition Clinical. **2012**, 27, 140-149

1496 Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. **2012**, 27, 1467-72 11

1495 Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy. **2012**, 27, 1461-6 1

1494 Natural killer cells in hepatitis C virus infection. **2012**, 8, 775-88 9

1493 Prediction of response to pegylated-interferon- α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. **2012**, 9, 123 16

1492 Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. **2012**, 42, 22-32 7

1491 Discovery of Boceprevir and Narlaprevir: The First and Second Generation of HCV NS3 Protease Inhibitors. **2012**, 296-335 3

1490 Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. **2012**, 27, 1842-9 39

1489 UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. **2012**, 35, 647-62 66

1488 Anti-hepatitis C virus drugs in development. **2012**, 142, 1340-1350.e1 75

1487 Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. **2012**, 56, 1611-21 19

1486 Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. **2012**, 56, 2134-41 37

1485 A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. *Journal of Medical Virology*, **2012**, 84, 1913-9 19.7 6

1484	Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. 2012 , 61, 1433-9	37	
1483	Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. 2012 , 47, 1228-37	12	
1482	An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. 2012 , 18, 689-97	4	
1481	Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment. 2012 , 2, 98-102	8	
1480	Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. 2012 , 12, 717-28	93	
1479	Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. 2012 , 57, 1186-92	41	
1478	An orally available, small-molecule interferon inhibits viral replication. 2012 , 2, 259	32	
1477	IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. 2012 , 31, 988-92	7	
1476	Pharmacogenomics of hepatitis C infections: personalizing therapy. 2012 , 4, 99	7	
1475	Challenges for HCV vaccine development in HIV-HCV coinfection. 2012 , 11, 791-804	8	
1474	Treatment failure with new hepatitis C drugs. 2012 , 13, 313-23	27	
1473	Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. 2012 , 50, 857-66	44	
1472	Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. 2012 , 90, 774-83	79	
1471	Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome. 2012 , 11, 717-27	16	
1470	Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. 2012 , 165, 236-40	9	
1469	The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment. 2012 , 6, 141-50	6	
1468	Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. <i>Liver International</i> , 2012 , 32, 826-36	7.9	30
1467	The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. <i>Liver International</i> , 2012 , 32, 962-9	7.9	18

1466	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. 2012 , 56, 34-40	75
1465	Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 2012 , 56, 313-9	34
1464	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. 2012 , 56, 267-75	133
1463	Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. 2012 , 56, 355-8	14
1462	Reply to IL28B polymorphism and hepatitis C: A genetic marker of peginterferon- α sensitivity devoid from classical interferon- α side effects? 2012 , 56, 742-743	
1461	IL28B polymorphism and hepatitis C: a genetic marker of peginterferon- α sensitivity devoid from classical interferon- α side effects?. 2012 , 56, 741-2; author reply 742-3	
1460	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. 2012 , 56, 527-32	149
1459	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. 2012 , 56, 788-94	33
1458	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. 2012 , 56, 1356-62	72
1457	Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. 2012 , 57, 32-8	28
1456	Interferon responses and spontaneous HCV clearance: is it all a matter of fat?. 2012 , 57, 3-5	3
1455	Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. 2012 , 57, 534-40	35
1454	Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment. 2012 , 26, 159-63	1
1453	The chemokine superfamily revisited. 2012 , 36, 705-16	691
1452	Interferon signaling in the liver during hepatitis C virus infection. 2012 , 59, 460-6	10
1451	P033 A multiplex RT-PCR assay for rapid and sensitive detection of cytokines in fish. 2012 , 59, 528-529	
1450	P034 Inhibition of macrophage migration inhibitory factor reduces dengue virus replication. 2012 , 59, 529	
1449	P035 A simple and reliable method for genotyping IL28B polymorphism in patients infected with hepatitis C virus. 2012 , 59, 529	

1448	P036 Japanese encephalitis virus nonstructural protein NS5 interacts with mitochondrial trifunctional protein and impairs long-chain fatty acid metabolism. 2012 , 59, 529		
1447	[Current indications for triple therapy in hepatitis C virus infection]. 2012 , 35, 266-77		
1446	Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium. 2012 , 91, 422-34		17
1445	Hepatitis C virus NS3/4A protease blocks IL-28 production. 2012 , 42, 2374-82		32
1444	Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. <i>Journal of Medical Virology</i> , 2012 , 84, 1593-9	19.7	6
1443	IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. <i>Journal of Medical Virology</i> , 2012 , 84, 1522-7	19.7	1
1442	Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. <i>Journal of Medical Virology</i> , 2012 , 84, 1744-50	19.7	67
1441	Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype. 2012 , 12, 158		8
1440	Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan. 2012 , 12, 167		1
1439	A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus. 2012 , 12, 31		21
1438	Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. 2012 , 12, 374		12
1437	Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. 2012 , 5, 508		23
1436	Distinct and overlapping genomic profiles and antiviral effects of Interferon- α and β on HCV-infected and noninfected hepatoma cells. 2012 , 19, 843-53		38
1435	Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco. 2012 , 16, 981-3		3
1434	Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees. 2012 , 7, e46645		4
1433	IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. 2012 , 7, e37054		75
1432	Host Gene Polymorphisms and Disease/Treatment Outcomes in HIV and Viral Coinfections. 2012 , 67-80		
1431	NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. 2012 , 50, 3886-92		17

1430	Natural history and clinical response: "it's the virus, stupid, or is it the host?". 2012 , 12 Suppl 2, S6	2
1429	Systems biology analyses to define host responses to HCV infection and therapy. 2013 , 363, 143-67	3
1428	Hepatitis C virus spontaneous clearance: immunology and genetic variance. 2012 , 25, 241-8	16
1427	Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development. 2012 , 31, 223-42	11
1426	Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. 2012 , 107, 669-89; quiz 690	77
1425	Host genetic variants in the pathogenesis of hepatitis C. <i>Viruses</i> , 2012 , 4, 3281-302	6.2 31
1424	The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India. 2012 , 2, 112-5	11
1423	Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. 2012 , 142, 78-85.e2	75
1422	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. 2012 , 142, 513-520.e1	134
1421	HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. 2012 , 142, 978-88	218
1420	Genetic factors and hepatitis C virus infection. 2012 , 142, 1335-9	14
1419	Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. 2012 , 143, 439-47.e1	28
1418	Factors that predict response of patients with hepatitis C virus infection to boceprevir. 2012 , 143, 608-618.e5	162
1417	Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. 2012 , 143, 1244-1252.e12	111
1416	Hepatobiliary quiz-3 (2012). 2012 , 2, 297-302	
1415	Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. 2012 , 1820, 1886-92	7
1414	Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study. 2012 , 2, 99-107	2
1413	The role of viral and host genetics in natural history and treatment of chronic HCV infection. 2012 , 26, 413-27	17

1412	Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. 2012 , 26, 429-44	13
1411	The bile salt export pump (BSEP) in health and disease. 2012 , 36, 536-53	120
1410	Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. 2012 , 24, 364-78	194
1409	Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon- β plus ribavirin: a meta-analysis. 2012 , 507, 27-35	14
1408	Relating human genetic variation to variation in drug responses. 2012 , 28, 487-95	58
1407	Measurement and clinical significance of interleukin 28B in hepatitis C virus-infected liver transplant patients. 2012 , 44, 2154-6	2
1406	Genomics and HCV infection: progression of fibrosis and treatment response. 2012 , 57, 1110-25	79
1405	The pharmacogenetic background of hepatitis C treatment. 2012 , 751, 36-48	6
1404	[Population genetics and human immunity: the interferon paradigm]. 2012 , 28, 1095-101	0
1403	Interferon stimulated genes and hepatitis C virus infection. <i>Journal of Interferon and Cytokine Research</i> , 2012 , 32, 557-62	3-5
1402	Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation. 2012 , 25, 379-86	16
1401	Reverse Genetic Tools to Study Hepatitis C Virus. 2012 , 64-90	
1400	High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus. 2012 , 47, 1053-62	2
1399	IL28B: Current and Future Use. 2012 , 11, 136-145	
1398	Telaprevir and Boceprevir: The Future Is Now. 2012 , 11, 160-171	2
1397	Hepatitis C Therapy: Lessons of the Last Two Decades. 2012 , 11, 119-127	1
1396	Biomarkers of Fibrosis and Fibrosis Progression in Chronic Hepatitis C. 2012 , 11, 231-242	
1395	Genetic variations in stem cell-related genes and colorectal cancer prognosis. 2012 , 43, 584-93	5

1394	Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. 2012 , 6, 744-52	7
1393	Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy. 2012 , 57, 370-4	3
1392	Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. 2012 , 205, 204-10	11
1391	Molecular Genetics and Personalized Medicine. 2012 ,	1
1390	Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient. 2012 , 10, 1117-28	2
1389	IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. 2012 , 26, 863-77	12
1388	New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. 2012 , 61 Suppl 1, i25-35	61
1387	Assessing gene-gene interactions in pharmacogenomics. 2012 , 16, 15-27	46
1386	Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. 2012 , 55, 1-11	22
1385	Chronic Hepatitis C Virus. 2012 ,	2
1384	High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ -glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study. 2012 , 86, 218-27	14
1383	A tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. 2012 , 31, 55-60	36
1382	Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. 2012 , 12, 324	7
1381	Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN- α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. 2012 , 7, e28115	6
1380	Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients. 2012 , 7, e29983	5
1379	Deciphering the interleukin 28B variants that better predict response to pegylated interferon- α and ribavirin therapy in HCV/HIV-1 coinfecting patients. 2012 , 7, e31016	34
1378	Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. 2012 , 7, e37998	42
1377	Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. 2012 , 7, e45698	23

1376	None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. 2012 , 7, e48217		3
1375	Pharmacogenomics: what is next?. 2011 , 2, 86		5
1374	Glances in Immunology of HIV and HCV Infection. 2012 , 2012, 434036		7
1373	An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. 2012 , 26, 359-75		62
1372	Quantifying liver cirrhosis by extracting significant features from MRI T2 image. 2012 , 2012, 343847		6
1371	Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology. 2012 , 45, 376-85		17
1370	Mutations in non-structural 5A and rapid viral response to pegylated interferon- α -2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. 2012 , 30, 1048-52		4
1369	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012 , 11, 284-293	3.1	17
1368	Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment. <i>Annals of Hepatology</i> , 2012 , 11, 827-837	3.1	6
1367	IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. <i>Annals of Hepatology</i> , 2012 , 11, 876-881	3.1	16
1366	Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C. 2012 , 48, 21-6		2
1365	HCV-Recurrence After Liver Transplantation. 2012 ,		
1364	Influence of interferon- α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B. 2012 , 2,		
1363	A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. 2012 , 107, 888-92		12
1362	New agents for the treatment of hepatitis C virus – focus on telaprevir. 2012 , 75		1
1361	Genetic Variation of Host Immune Response Genes and Their Effect on Hepatitis C Infection and Treatment Outcome. 2012 ,		1
1360	Genomics and proteomics in liver fibrosis and cirrhosis. 2012 , 5, 1		42
1359	Whole-genome sequencing in personalized therapeutics. 2012 , 91, 1001-9		33

1358	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. 2012 , 47, 1143-51		14
1357	Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. 2012 , 47, 596-605		32
1356	Randomized trial of peginterferon α -2a plus ribavirin versus peginterferon α -2b plus ribavirin for chronic hepatitis C in Japanese patients. 2012 , 47, 1014-21		16
1355	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. 2012 , 47, 834-44		17
1354	IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. 2012 , 28, 1640-6		12
1353	Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. <i>Journal of Medical Virology</i> , 2012 , 84, 1097-105	19.7	18
1352	Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2012 , 84, 1199-207	19.7	9
1351	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. 2012 , 55, 1700-10		70
1350	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 2012 , 56, 444-54		59
1349	Clinical utility of interleukin-28B testing in patients with genotype 1. 2012 , 56, 367-72		12
1348	Introduction to the genetics and biology of interleukin-28B. 2012 , 56, 361-6		19
1347	Lost in translation? IL28B's discovery and the journey back to the patient. 2012 , 56, 5-8		1
1346	S-adenosylmethionine (SAME) therapy in liver disease: a review of current evidence and clinical utility. 2012 , 57, 1097-109		150
1345	The interferon-dependent orchestration of innate and adaptive immunity after transplantation. 2012 , 119, 5351-8		35
1344	Predicting the response to the treatment of hepatitis C virus infection. 2012 , 1, 46-48		1
1343	The new standard of HCV therapy: Retreatment in experienced patients. 2012 , 1, 16-19		
1342	Genetics of IL28B and HCV--response to infection and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012 , 9, 406-17	24.2	86
1341	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. 2012 , 55, 231-41		16

1340	Functional genomic studies: insights into the pathogenesis of liver cancer. 2012 , 13, 171-205		82
1339	Novel therapies for hepatitis C: insights from the structure of the virus. 2012 , 63, 373-87		35
1338	Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. 2012 , 6, 468-74		3
1337	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. 2012 , 6, 482-90		15
1336	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. 2012 , 6, 613-9		4
1335	APASL consensus statements and management algorithms for hepatitis C virus infection. 2012 , 6, 409-35		139
1334	Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. 2012 , 47, 334-42		2
1333	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , 2012 , 32 Suppl 1, 2-8	7.9	83
1332	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012 , 32 Suppl 1, 135-40	7.9	11
1331	IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?. <i>Liver International</i> , 2012 , 32 Suppl 1, 74-8	7.9	17
1330	Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. <i>Liver International</i> , 2012 , 32 Suppl 1, 44-50	7.9	19
1329	Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. 2012 , 27, 69-75		9
1328	Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. 2012 , 27, 279-85		21
1327	Host genomics and HCV treatment response. 2012 , 27, 212-22		25
1326	Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. 2012 , 19, 94-102		2
1325	Serum PAI-1 is a novel predictor for response to pegylated interferon- α -2b plus ribavirin therapy in chronic hepatitis C virus infection. 2012 , 19, e126-33		5
1324	Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease. 2012 , 19 Suppl 1, 1-2		
1323	New developments in HCV therapy. 2012 , 19 Suppl 1, 48-51		31

1322	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. 2012 , 19, e134-42	107
1321	Implications of rapid virological response in hepatitis C therapy in the US veteran population. 2012 , 35, 105-15	8
1320	Enhancing predictive ability of IL28B-SNPs for SVR in HCV. 2012 , 35, 317-8	1
1319	Human genetic susceptibility to infectious disease. 2012 , 13, 175-88	327
1318	Living in the liver: hepatic infections. 2012 , 12, 201-13	367
1317	Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. 2012 , 36, 663-83	96
1316	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. 2012 , 93, 239-244	42
1315	Evaluation of susceptibility locus for response to interferon- β based therapy in chronic hepatitis B patients in Chinese. 2012 , 93, 297-300	38
1314	Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay. 2012 , 94, 54-6	9
1313	Polymorphisms in ADAR1 gene affect response to interferon alpha based therapy for chronic hepatitis B in Han Chinese. 2012 , 94, 272-5	10
1312	Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). 2012 , 271, 366-78	39
1311	Hepatic transplant and HCV: a new playground for an old virus. 2012 , 12, 298-305	17
1310	Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. 2012 , 12, 737-44	24
1309	Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population. 2012 , 39, 346-52	12
1308	Weight-based high- and low-dose ribavirin in combination with peginterferon β -2b therapy for genotype 2 chronic hepatitis C: A randomized trial. 2012 , 42, 351-8	1
1307	Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years. 2012 , 42, 637-47	9
1306	Efficacy of reduction therapy of natural human β interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. 2012 , 42, 750-6	6
1305	Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. 2012 , 42, 854-63	13

1304	Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication. 2012 , 42, 841-53	2
1303	Efficacy of reduction therapy of natural human Interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. 2012 , 42, 949-57	7
1302	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. 2012 , 42, 958-65	7
1301	Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy. 2012 , 42, 966-73	
1300	Development of specific and quantitative real-time detection PCR and immunoassays for B-interferon. 2012 , 42, 1089-99	11
1299	Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment. 2012 , 42, 1157-67	12
1298	Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV. 2012 , 184, 103-5	6
1297	A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. 2012 , 184, 93-7	10
1296	In vitro models for analysis of the hepatitis C virus life cycle. 2012 , 56, 1-9	6
1295	Development of new IL28B genotyping method using Invader Plus assay. 2012 , 56, 318-23	5
1294	Hepatocellular carcinoma: towards personalized medicine. 2012 , 103, 846-50	39
1293	The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. 2012 , 35, 1209-20	7
1292	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. 2012 , 35, 1434-42	32
1291	Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon- α and ribavirin. 2012 , 36, 91-103	50
1290	Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. 2012 , 36, 104-14	35
1289	Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. 2012 , 36, 353-62	34
1288	IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. 2012 , 42, 599-606	23
1287	IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. 2012 , 19, 173-81	60

1286	Lymphotropic hepatitis C virus has an interferon-resistant phenotype. 2012 , 19, 254-62		8
1285	Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 2012 , 19, 332-40		29
1284	A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. 2012 , 19 Suppl 2, 1-26		60
1283	IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. 2012 , 79, 302-5		26
1282	Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease. 2012 , 14, 488-95		9
1281	Human T-cell leukemia virus type 1 infection worsens prognosis of hepatitis C virus-related living donor liver transplantation. 2012 , 25, 433-8		6
1280	Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C. 2012 , 27, 1112-6		3
1279	Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment. 2012 , 27, 425-9		9
1278	Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. 2012 , 9, 40		11
1277	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. 2012 , 55, 20-9		52
1276	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. 2012 , 55, 384-94		124
1275	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. 2012 , 55, 336-42		67
1274	Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. <i>Journal of Medical Virology</i> , 2012 , 84, 61-70	19.7	8
1273	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin. <i>Journal of Medical Virology</i> , 2012 , 84, 438-44	19.7	19
1272	Treatment of non-genotype 1 hepatitis C virus patients. 2012 , 14, 87-93		7
1271	IL28B: Implications for Clinical Practice. 2012 , 11, 15-22		
1270	Acute HCV: Will IL28B Testing Change the Paradigm?. 2012 , 11, 10-14		1
1269	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. 2012 , 6, 386-96		29

1268	IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?. 2012 , 6, 356-9		3
1267	Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. 2012 , 360, 9-14		11
1266	Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon- β and ribavirin therapy for chronic hepatitis C patients. 2012 , 47, 169-78		8
1265	SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. 2013 , 33, 1110-6		7
1264	Epidemiologic Studies in Cancer Prevention and Screening. 2013 ,		4
1263	Novel therapies for hepatitis C - one pill fits all?. 2013 , 12, 595-610		156
1262	IL28B genotype and the expression of ISGs in normal liver. <i>Liver International</i> , 2013 , 33, 991-8	7.9	16
1261	Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. 2013 , 11, 6		72
1260	Pharmacogenetics and Pharmacogenomics. 2013 , 1-27		
1259	Susceptibility and Response to Infection. 2013 , 1-24		1
1258	IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. 2013 , 7, 533-8		20
1257	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. 2013 , 7, 144-52		7
1256	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. 2013 , 7, 153-61		4
1255	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. 2013 , 7, 171-9		5
1254	Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?. 2013 , 48, 555-6		1
1253	Inhibition of hepatocellular carcinoma by PegIFN β -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. 2013 , 48, 382-90		18
1252	Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia. 2013 , 12, 165-173		
1251	Molecular Epidemiology of HCV in Asia. 2013 , 12, 133-142		1

1250	IL28B Genotype on HCV Infection in Asia. 2013 , 12, 149-156		2
1249	Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. 2013 , 63, 145-50		3
1248	Impact of host and virus genome variability on HCV replication and response to interferon. 2013 , 3, 501-7		5
1247	IL28B und antivirale Therapie der Virushepatitis: Was bleibt?. 2013 , 8, 322-329		
1246	Treatment of hepatitis C virus infection in the future. 2013 , 2, 9		25
1245	Update on epidemiology of hepatitis B and C in China. 2013 , 28 Suppl 1, 7-10		235
1244	The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. 2013 , 58, 254-7		7
1243	A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. 2013 , 58, 875-82		50
1242	Induction of interferon- λ contributes to Toll-like receptor-3-activated hepatic stellate cell-mediated hepatitis C virus inhibition in hepatocytes. 2013 , 20, 385-94		12
1241	Immunology taught by human genetics. 2013 , 78, 157-72		48
1240	Interferon-stimulated genes and their role in controlling hepatitis C virus. 2013 , 59, 1331-41		72
1239	A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. <i>Journal of Medical Virology</i> , 2013 , 85, 1746-53	19.7	11
1238	Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype. 2013 , 19, 63-9		3
1237	The impact of ethnicity on hepatitis C virus treatment decisions and outcomes. 2013 , 58, 621-9		3
1236	Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). 2013 , 37, 10-6		19
1235	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. 2013 , 32, 1427-35		9
1234	Lead-in treatment with interferon- λ /ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. 2013 , 28, 443-9		2
1233	Cost-effectiveness of viral hepatitis B & C treatment. 2013 , 27, 973-85		11

1232	Progress towards a hepatitis C virus vaccine. 2013 , 2, e79		35
1231	Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. 2013 , 16, 60-7		13
1230	Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. 2013 , 20, 418-21		11
1229	Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. 2013 , 19, 193-202		11
1228	Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. 2013 , 38, 1076-85		21
1227	Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. 2013 , 20, 263-72		16
1226	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. 2013 , 20, 470-7		22
1225	Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. 2013 , 99, 119-24		20
1224	Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. <i>Journal of Medical Virology</i> , 2013 , 85, 1028-36	19.7	27
1223	'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. 2013 , 94, 1259-1265		18
1222	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. 2013 , 58, 1918-29		233
1221	Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study. 2013 , 40, 6189-94		3
1220	Role of viral and host factors in interferon based therapy of hepatitis C virus infection. 2013 , 10, 299		26
1219	Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. 2013 , 32, 745-54		29
1218	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (80% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. 2013 , 7, 1000-9		1
1217	The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. 2013 , 444, 292-300		28
1216	Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells. 2013 , 64, 577-83		10
1215	CCR5-B2 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. <i>Genes and Immunity</i> , 2013 , 14, 286-90	4.4	5

1214	Next generation sequencing and rare genetic variants: from human population studies to medical genetics. 2013 , 54, 518-32		8
1213	Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. 2013 , 94, 81-89		9
1212	Liver immunology. 2013 , 3, 567-98		96
1211	Insights from genome-wide association studies of drug response. 2013 , 53, 299-310		29
1210	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 2013 , 100, 114-9		25
1209	Human type 2 myeloid dendritic cells produce interferon- β and amplify interferon- β in response to hepatitis C virus infection. 2013 , 144, 414-425.e7		90
1208	IL28B Polymorphisms Among Latin American HCV Patients. 2013 , 12, 276-279		1
1207	Meloxicam as an adjuvant to peginterferon- α 2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. 2013 , 43, 925-32		
1206	Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2013 , 85, 1180-90	19.7	8
1205	P18: Samatasvir (IDX719), a potent pan-genotypic HCV NS5A inhibitor. 2013 , 20, 25-26		1
1204	Interleukin-28B polymorphisms and hepatitis C virus clearance. 2013 , 5, 6		3
1203	Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance. 2013 , 31, 421-5		1
1202	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load. 2013 , 31, 426-33		2
1201	Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. 2013 , 43, 1-34		55
1200	Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. 2013 , 62, 766-73		22
1199	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. 2013 , 513, 292-6		22
1198	Innate immunity and HCV. 2013 , 58, 564-74		113
1197	Omics and drug response. 2013 , 53, 475-502		112

1196	Hepatitis C virus kinetics by administration of pegylated interferon- β in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. 2013 , 62, 1340-6		21
1195	Host factors determining the efficacy of hepatitis C treatment. 2013 , 48, 22-30		24
1194	Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. 2013 , 61, 478-84		42
1193	The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 15-23	3.5	28
1192	Hepatitis C vaccines. 2013 , 1074-1084		
1191	Immunity and hepatitis C: a review. 2013 , 10, 51-8		22
1190	Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. 2013 , 43, 327-38		9
1189	IL-28B (IFN- β) and IFN- α synergistically inhibit HCV replication. 2013 , 20, 281-9		24
1188	HCV in liver transplantation. 2013 , 35, 101-10		10
1187	Antiviral activity of the interferon β family: biological and pharmacological aspects of the treatment of chronic hepatitis C. 2013 , 13, 693-711		19
1186	Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. <i>Journal of Medical Virology</i> , 2013 , 85, 65-70	19.7	4
1185	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2013 , 85, 250-60	19.7	14
1184	Synthetic lipophilic antioxidant BO-653 suppresses HCV replication. <i>Journal of Medical Virology</i> , 2013 , 85, 241-9	19.7	5
1183	Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment. <i>Journal of Medical Virology</i> , 2013 , 85, 441-8	19.7	12
1182	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2013 , 85, 449-58	19.7	9
1181	Interleukin-28B polymorphism in hepatitis C and liver transplantation. 2013 , 19, 49-58		17
1180	Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. 2013 , 28, 51-6		17
1179	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. <i>Nature Genetics</i> , 2013 , 45, 164-71	36.3	704

1178	Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay. 2013 , 189, 221-7	15
1177	Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. 2013 , 59, 504-9	65
1176	Genomics and transcriptomics in HIV and HIV/HCV coinfection Review of basic concepts and genome-wide association studies. 2013 , 12, 97-101	1
1175	Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. 2013 , 58, 969-76	13
1174	Serum level of interleukin-10 with its gene polymorphism can be predictors of response to treatment in Egyptian patients with chronic hepatitis C virus. 2013 , 14, 227-233	6
1173	Management of recurrent hepatitis C in orthotopic liver transplant recipients. 2013 , 27, 285-304	1
1172	Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use. 2013 , 16, S16-9	5
1171	Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. 2013 , 443, 80-8	16
1170	Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis. 2013 , 62, 1577-86	18
1169	The impact of network medicine in gastroenterology and hepatology. 2013 , 11, 1240-4	10
1168	Glucose abnormalities in hepatitis C virus infection. 2013 , 29, 61-8	20
1167	IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. 2013 , 20, 59-64	38
1166	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 2013 , 20, 113-21	16
1165	Hepatitis C virus vaccines in the era of new direct-acting antivirals. 2013 , 7, 171-85	9
1164	A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. 2013 , 43, 35-43	9
1163	The importance of IL28B genotype in hepatitis C virus-associated liver transplantation. <i>Liver International</i> , 2013 , 33, 169-71	7.9 2
1162	Population genetic tools for dissecting innate immunity in humans. 2013 , 13, 280-93	87
1161	Innate immune responses to hepatitis C virus. 2013 , 369, 219-42	34

1160	Interleukin 28B rs12979860 (CT/TT) genotype is associated with milder hepatic damage in the natural evolution of HCV/HIV coinfection. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 43-7	3.5	2
1159	Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. 2013 , 43, 919-24		1
1158	Loss of function of the new interferon IFN- λ may confer protection from hepatitis C. <i>Nature Genetics</i> , 2013 , 45, 119-20	36.3	32
1157	Systematic review: Asian patients with chronic hepatitis C infection. 2013 , 37, 921-36		97
1156	The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. 2013 , 8, e54854		9
1155	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. 2013 , 58, 883-9		46
1154	Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. 2013 , 58, 439-41		8
1153	Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis. 2013 , 28, 1114-21		7
1152	IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. 2013 , 20, 358-66		15
1151	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. 2013 , 58, 1548-57		89
1150	The genetic theory of infectious diseases: a brief history and selected illustrations. 2013 , 14, 215-43		98
1149	IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. 2013 , 57, 890-6		127
1148	Natural selection in a bangladeshi population from the cholera-endemic ganges river delta. 2013 , 5, 192ra86		57
1147	Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C. 2013 , 43, 1139-47		5
1146	Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. 2013 , 19, 859-68		328
1145	Regulation of hepatic innate immunity by hepatitis C virus. 2013 , 19, 879-88		214
1144	Current progress in development of hepatitis C virus vaccines. 2013 , 19, 869-78		121
1143	25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. 2013 , 13, 535-42		112

1142	Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. 2013 , 45, 1-7		23
1141	Advances in the management of hepatitis C. 2013 , 43, 1265-71		3
1140	Personalizing health care: feasibility and future implications. 2013 , 11, 179		63
1139	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 2013 , 210, 1109-16		179
1138	IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfecting with hepatitis C virus. 2013 , 66, 170-8		13
1137	Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. 2013 , 19, 1827-37		47
1136	Microbial translocation in the pathogenesis of HIV infection and AIDS. 2013 , 26, 2-18		310
1135	One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. 2013 , 57, 870-2		8
1134	IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfecting and HCV mono-infected patients. 2013 , 63, 9-16		12
1133	Clinical developments. 2013 , 129-145		
1132	Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?. 2013 , 14, 1-4		7
1131	Multiple sclerosis: individualized disease susceptibility and therapy response. 2013 , 7, 59-71		6
1130	Confounding and heterogeneity in genetic association studies with admixed populations. 2013 , 177, 351-60		36
1129	Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. <i>Hepatitis Monthly</i> , 2013 , 13, e14872	1.8	12
1128	Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. <i>Hepatitis Monthly</i> , 2013 , 13, e13678	1.8	13
1127	Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection. <i>Hepatitis Monthly</i> , 2013 , 13, e8988	1.8	2
1126	Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C. 2013 , 47, 794-9		1
1125	Genetic and epigenetic susceptibility to early life infection. 2013 , 26, 241-7		10

1124	A genome-wide perspective of human diversity and its implications in infectious disease. 2013 , 3, a012450	21
1123	Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection. 2013 , 44, 292-299	6
1122	HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. 2013 , 56, 1695-703	52
1121	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. 2013 , 87, 5270-86	138
1120	Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B. 2013 , 48, 745-51	7
1119	Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon- β and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. 2013 , 43, 1005-12	3
1118	In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 2013 , 98, 423-9	6
1117	Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. 2013 , 56, 13-21	14
1116	Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy. 2013 , 31, 434-9	3
1115	Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. 2013 , 47, 644-50	15
1114	IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon- β . 2013 , 28, 861-6	37
1113	Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. 2013 , 51, 2862-8	20
1112	Interferon- β -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections. 2013 , 2013, 374196	2
1111	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B. 2013 , 43, 580-8	2
1110	Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon- β plus ribavirin in patients with chronic hepatitis C. 2013 , 43, 743-56	5
1109	Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. 2013 , 43, 865-75	1
1108	Viral hepatitis C gets personal--the value of human genomics to public health. 2013 , 16, 192-7	6
1107	Ophthalmologic complications of antiviral therapy in hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8227-37	5.6 7

1106	High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. 2013 , 87, 9707-18		43
1105	Emerging Viral Infections. 2013 , 1142-1154		2
1104	Interferon- λ (IFNL4) transcript expression in human liver tissue samples. 2013 , 8, e84026		45
1103	New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection. <i>Journal of Medical Virology</i> , 2013 , 85, 1523-33	19.7	9
1102	Natural history of hepatitis C in thalassemia major: a long-term prospective study. 2013 , 90, 501-7		25
1101	Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia. 2013 , 20, 838-46		1
1100	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. 2013 , 20, 790-800		10
1099	P16: Analysis of genetic determinants associated with therapy response against hepatitis C virus: first study of IL28B polymorphisms in Uruguayan patients. 2013 , 20, 24-25		
1098	Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1. <i>Journal of Medical Virology</i> , 2013 , 85, 1163-9	19.7	5
1097	An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C. 2013 , 20, e124-6		5
1096	Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy. 2013 , 43, 801-7		6
1095	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. 2013 , 20, e107-14		15
1094	Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese. <i>Journal of Medical Virology</i> , 2013 , 85, 1206-14	19.7	1
1093	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. 2013 , 110, 7844-9		55
1092	Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. 2013 , 87, 12541-51		30
1091	[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection]. 2013 , 154, 1261-8		5
1090	Sustained and rapid virological responses in hepatitis C clinical trials. 2013 , 3, 1083-1093		2
1089	Genomics. 2013 , 9-48		

1088	Low-dose pegylated interferon- α 2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load. 2014 , 19, 107-15	4
1087	Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. 2013 , 27, 2817-9	11
1086	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon- γ in response to hepatitis C virus. 2013 , 57, 1705-15	74
1085	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. 2013 , 27, 687-96	9
1084	Genome-wide association studies in pharmacogenomics: successes and lessons. 2013 , 23, 383-94	109
1083	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. 2013 , 27, 163-73	10
1082	Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease. 2013 , 95, 203-8	5
1081	HBV genotype F: natural history and treatment. 2013 , 18, 485-8	20
1080	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. 2013 , 19, 5219-38	148
1079	IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. 2013 , 18, 599-606	9
1078	A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. 2013 , 3, 1065	236
1077	[The 40th scientific meeting: perspectives of internal medicine; present situation and future extension of organ transplantation in Japan; 6. Viral hepatitis and liver transplantation]. 2013 , 102, 573-81	
1076	The natural killer cell response to HCV infection. 2013 , 13, 168-76	17
1075	Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. 2013 , 10, 43-9	3
1074	Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. 2013 , 10, 1015-21	8
1073	Association of the interleukin-28B gene polymorphism with development of hepatitis virus-related hepatocellular carcinoma and liver cirrhosis: a meta-analysis. 2013 , 12, 3708-17	16
1072	Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. 2013 , 108, 48-53	6
1071	Viral Hepatitis. 2013 , 1173-1190	

1070	Platelet count and sustained virological response in hepatitis C treatment. 2013 , 5, 182-8		8
1069	Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6957-61	5.6	9
1068	Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes. 2013 , 18, 1027-32		5
1067	Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. 2013 , 8, e54793		32
1066	Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. 2013 , 8, e56991		11
1065	Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. 2013 , 8, e58380		1
1064	Targeted induction of interferon- β in humanized chimeric mouse liver abrogates hepatotropic virus infection. 2013 , 8, e59611		32
1063	Albumin fusion of interleukin-28B: production and characterization of its biological activities and protein stability. 2013 , 8, e64301		4
1062	Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. 2013 , 8, e66831		11
1061	Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. 2013 , 8, e69166		23
1060	Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. 2013 , 8, e72600		9
1059	A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF- κ B-mediated gene transcription. 2013 , 8, e75495		20
1058	CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. 2013 , 8, e76798		14
1057	microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. 2013 , 8, e76867		33
1056	Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. 2013 , 8, e77530		7
1055	Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. 2013 , 8, e80003		8
1054	Impact of IL28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. 2013 , 8, e80172		22
1053	No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. 2013 , 8, e81312		25

1052	Hepatitis C virus infection and related liver disease: the quest for the best animal model. 2013 , 4, 213		30
1051	Hepatitis C virus adaptation to T-cell immune pressure. 2013 , 2013, 673240		11
1050	Epidemiology and treatment of hepatitis C genotypes 5 and 6. 2013 , 27, e8-12		18
1049	Patients younger than forty years old with hepatitis C virus genotype1 chronic infection had treatment responses similar to genotype2 infection and not related to interleukin28B polymorphism. <i>Annals of Hepatology</i> , 2013 , 12, 62-69	3.1	3
1048	Modeling the Pharmacogenetic Architecture of Drug Response. 2013 , 295-308		1
1047	Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. 2014 ,		
1046	IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. 2014 , 9, e91316		7
1045	Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. 2014 , 9, e94760		31
1044	Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C. 2014 , 9, e97078		8
1043	Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. 2014 , 9, e99126		10
1042	Clinical significance of the CCR5delta32 allele in hepatitis C. 2014 , 9, e106424		7
1041	The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. 2014 , 28, 481-7		6
1040	Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9633-52	5.6	113
1039	Lessons from Genome-Wide Search for Disease-Related Genes with Special Reference to HLA-Disease Associations. 2014 , 5, 84-96		3
1038	Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. 2014 , 5, 305		15
1037	Clinical utility of pharmacogenomics in the management of hepatitis C. 2014 , 7, 339-47		2
1036	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. 2014 , 5,		1
1035	Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response. 2014 , 4, 11-20		1

1034	Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. <i>Annals of Hepatology</i> , 2014 , 13, 525-532	3.1	21
1033	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. 2014 , 29, 102-9		6
1032	Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. 2014 , 44, 1277-85		9
1031	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014 , 159, 3345-51	2.6	3
1030	Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. 2014 , 15, 104		4
1029	A Genome-Wide Screen for Large-Effect Alloimmunization Susceptibility Loci among Red Blood Cell Transfusion Recipients with Sickle Cell Disease. 2014 , 41, 453-61		15
1028	Outflanking HCV. 2014 , 15, 6-8		3
1027	Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. <i>Genes and Immunity</i> , 2014 , 15, 88-94	4.4	18
1026	Post-transcriptional regulation of interferons and their signaling pathways. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 318-29	3.5	38
1025	Hepatitis C Virus. Strategies to Evade Antiviral Responses. 2014 , 9, 1061-1075		26
1024	Quantitative genetics in the study of virus-induced disease. 2014 , 88, 193-225		6
1023	Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients. 2014 , 33, 642-6		2
1022	Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. 2014 , 12, e1001758		46
1021	The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. 2014 , 15, 7213-24		17
1020	Screening for 392 polymorphisms in 141 pharmacogenes. <i>Biomedical Reports</i> , 2014 , 2, 463-476	1.8	9
1019	Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?. 2014 , 14 Suppl 5, S5		6
1018	Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). 2014 , 10, e1004681		66
1017	Contradictory immune response in post liver transplantation hepatitis B and C. 2014 , 2014, 814760		2

1016	IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. 2014 , 10, e1004556		72
1015	Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population. 2014 , 15, 9826-43		7
1014	Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. 2014 , 2014, 549709		2
1013	Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. 2014 , 2014, 748935		4
1012	Protective immunity against hepatitis C: many shades of gray. 2014 , 5, 274		65
1011	Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. 2014 , 9, e87773		12
1010	Personalized medicine and the clinical laboratory. 2014 , 12, 366-73		3
1009	The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. <i>Hepatitis Monthly</i> , 2014 , 14, e22649	1.8	21
1008	Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. 2014 , 5, 545		16
1007	The association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients. 2014 , 2014, 357062		14
1006	SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. 2014 , 2014, 748606		8
1005	Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. 2014 , 4, e006255		1
1004	IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfecting patients. 2014 , 28, 133-6		30
1003	HIV-1 Tat clade-specific cytokine induction in monocytes/macrophages is not evidenced in total or VβVβ T lymphocytes. 2014 , 28, 131-3		1
1002	Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report. 2014 , 7, 141		1
1001	IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. 2014 , 21, 525-32		22
1000	IL28B rs 12979860 predicts response to treatment in Egyptian hepatitis C virus genotype 4 patients and alpha fetoprotein increases its predictive strength. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 505-9	3.5	7
999	Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. 2014 , 40, 811-8		16

998	Prediction of efficacy to pegylated interferon- β -2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. 2014 , 44, 179-86		6
997	Variation in genes encoding for interferon β and β 4 in the prediction of HCV-1 treatment-induced viral clearance. <i>Liver International</i> , 2014 , 34, 1369-77	7.9	7
996	Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. 2014 , 210, 717-27		59
995	Genetic polymorphism in IFNL4 and response to pegylated interferon- β and ribavirin in Japanese chronic hepatitis C patients. 2014 , 83, 45-8		10
994	Tributyltin(IV)[3-(3,5-dimethylphenylamido)propanoate] as a potent HCV inhibitor, its delivery study, controlled release and binding sites using CTAB as a standard cell membrane. 2014 , 28, 74-80		4
993	Polymorphisms of interferon- β and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. 2014 , 39, 104-11		50
992	Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway. 2014 , 60, 1519-30		30
991	Anti-interferon- β neutralizing antibody induced telaprevir resistance under the interferon- β plus telaprevir treatment in vitro. 2014 , 454, 453-8		2
990	Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load. 2014 , 44, 728-34		
989	Exploration of genetically determined resistance against hepatitis C infection in high-risk injecting drug users. 2014 , 21, e65-73		12
988	Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohort. 2014 , 38, 720-6		1
987	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan. <i>Journal of Medical Virology</i> , 2014 , 86, 1877-85 ^{19.7}		4
986	The interaction of a single-nucleotide polymorphism with age on response to interferon- β and ribavirin therapy in female patients with hepatitis C infection. <i>Journal of Medical Virology</i> , 2014 , 86, 1130-3 ^{19.7}		
985	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. 2014 , 29, 1458-62		4
984	Adjuvant epoetin- α with peginterferon- β and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. 2014 , 44, E290-6		0
983	Innate and adaptive immune responses in HCV infections. 2014 , 61, S14-25		183
982	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. 2014 , 44, 983-92		3
981	Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. 2014 , 29, 545-53		95

980	A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced. <i>Liver International</i> , 2014 , 34, 1560-5	7.9	5
979	Commentary: the ss469415590 SNP--an IL28B marker looking for a home. 2014 , 39, 339		
978	IFN- β -Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. <i>Journal of Medical Virology</i> , 2014 , 86, 461-72	19.7	6
977	Role of IFN- α s, IFN- α s related genes and the DEPDC5 gene in Hepatitis B virus-related liver disease. 2014 , 21, e29-38		10
976	Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1. 2014 , 44, 410-9		3
975	Reduced IFN α activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. 2014 , 5, 5699		95
974	Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients. <i>Journal of Medical Virology</i> , 2014 , 86, 241-7	19.7	9
973	Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment. 2014 , 44, 597-607		2
972	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. <i>Journal of Medical Virology</i> , 2014 , 86, 1314-22	19.7	19
971	In vitro blood cell responsiveness to IFN- β predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. 2014 , 12, 206		4
970	World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013. 2014 , 48, 204-17		9
969	Prediction of response to pegylated interferon and ribavirin in Egyptian patients with chronic hepatitis C using serum neopterin. 2014 , 4, 63-68		
968	Current challenges and the management of chronic hepatitis C in mainland China. 2014 , 48, 679-86		40
967	Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients. 2014 , 48, 73-9		
966	Pharmacogenetics at 50: genomic personalization comes of age. 2014 , 6, 220ps1		18
965	Predictors of hepatitis C treatment response: what's new?. 2014 , 12, 183-91		2
964	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. 2014 , 2014, 723868		9
963	Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. 2014 , 44, 1165-71		12

962	Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. 2014 , 29, 179-84	7
961	Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy. 2014 , 57, 289-96	1
960	Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. 2014 , 57, 311-8	19
959	Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. 2014 , 44, E360-7	32
958	Pretreatment prediction of the outcome of response-guided peginterferon- α and ribavirin therapy for chronic hepatitis C. 2014 , 29, 1996-2005	2
957	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. 2014 , 102, 35-43	25
956	Fibrosing cholestatic hepatitis developing within one month after living donor liver transplantation for chronic hepatitis C-related cirrhosis: a case report. 2014 , 46, 995-8	4
955	Hepatitis C treatment: an incipient therapeutic revolution. 2014 , 20, 315-21	41
954	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. 2014 , 146, 744-753.e3	37
953	Impact of new hepatitis C treatments in different regions of the world. 2014 , 146, 1145-50.e1-4	44
952	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 2014 , 106, 105-10	9
951	Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. 2014 , 59, 1262-72	126
950	Kinetic differences in the induction of interferon stimulated genes by interferon- α and interleukin 28B are altered by infection with hepatitis C virus. 2014 , 59, 1250-61	75
949	Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. <i>Archives of Virology</i> , 2014 , 159, 1-15	2.6 6
948	Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin. 2014 , 29, 201-7	11
947	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. 2014 , 49, 1152-62	26
946	IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. 2014 , 49, 748-54	12
945	Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. 2014 , 49, 737-47	3

944	Ex vivo induction of IFN- β by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. 2014 , 49, 126-37		16
943	Impact of the peginterferon- β 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes. 2014 , 21, 178-88		6
942	Application of Translational Science to Clinical Development. 2014 , 1-21		
941	IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. 2014 , 7, 12		8
940	Cell therapies and regenerative medicine. 2014 , 8, 158-65		
939	Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection. <i>Archives of Virology</i> , 2014 , 159, 1365-71	2.6	4
938	A rationalized approach to the treatment of patients infected with hepatitis B. 2014 , 18, 203-12		1
937	Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. 2014 , 49, 1485-94		6
936	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. 2014 , 44, E447-54		12
935	Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. 2014 , 13, 178-86		46
934	Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. 2014 , 105, 112-7		10
933	A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. 2014 , 44, E386-96		3
932	Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. 2014 , 44, E397-E407		11
931	Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. 2014 , 104, 102-9		7
930	Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. 2014 , 44, 1208-1216		8
929	Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. 2014 , 52, 193-200		14
928	Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. 2014 , 29, 144-50		18
927	IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. 2014 , 95, 1297-1306		11

926	Role of IL28B for chronic hepatitis C treatment toward personalized medicine. 2014 , 29, 241-9		38
925	Activation and evasion of antiviral innate immunity by hepatitis C virus. 2014 , 426, 1198-209		53
924	Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. 2014 , 101, 37-44		6
923	The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies. <i>Archives of Virology</i> , 2014 , 159, 527-34	2.6	3
922	Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. 2014 , 49, 363-8		3
921	Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. 2014 , 49, 1253-63		5
920	The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. 2014 , 39, 322-30		20
919	Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. 2014 , 21, e98-e107		23
918	Murine models of hepatitis C: what can we look forward to?. 2014 , 104, 15-22		26
917	Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2014 , 86, 224-34	19.7	4
916	Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. 2014 , 61, 219-27		128
915	Hepatitis C virus and human miR-122: insights from the bench to the clinic. 2014 , 7, 11-8		26
914	Hepatitis C virus and microRNAs: miRed in a host of possibilities. 2014 , 7, 1-10		30
913	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. 2014 , 44, 945-54		26
912	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfecting patients. 2014 , 60, 477-86		9
911	Hepatitis C Virus. 2014 , 859-877		
910	Review article: genetic factors that modify the outcome of viral hepatitis. 2014 , 39, 1059-70		42
909	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. 2014 , 59, 828-38		34

908	IFN- λ : the paradoxical new member of the interferon lambda family. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 829-38	3.5	103
907	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. 2014 , 61, 235-41		33
906	Activation of endogenous type I IFN signaling contributes to persistent HCV infection. 2014 , 24, 332-42		19
905	Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. 2014 , 20, 2541-52		39
904	Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 106-10	3.5	6
903	Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment. 2014 , 52, 2193-5		1
902	Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. 2014 , 14, 549-54		10
901	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. <i>Liver International</i> , 2014 , 34, 890-5	7.9	15
900	Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension. 2014 , 33, 277-300		15
899	Abasic site-binding ligands conjugated with cyanine dyes for "off-on" fluorescence sensing of orphan nucleobases in DNA duplexes and DNA-RNA hybrids. 2014 , 50, 515-7		21
898	Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. 2014 , 33, 559-67		30
897	Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 2014 , 18, 25-38		1
896	Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection. 2014 , 209, 1591-601		8
895	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. 2014 , 49, 1548-56		18
894	Association of IL28B polymorphism with fibrosis, liver inflammation, gender respective natural history of hepatitis C virus in Egyptian patients with genotype 4. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 22-7	3.5	8
893	Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. 2014 , 68, 1-20		61
892	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon- λ -based regimens. 2014 , 95, 141-6		66
891	Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. 2014 , 17, 77-87		16

890	Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. 2014 , 209, 1907-15		21
889	Therapeutic vaccines against hepatitis C virus. 2014 , 22, 120-9		17
888	Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. 2014 , 21, 8-14		14
887	Immune responses to HCV and other hepatitis viruses. 2014 , 40, 13-24		193
886	IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. 2014 , 20, 598-605		15
885	Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective. 2014 , 11, 111-6		11
884	Predictors of the therapeutic response in hepatitis C. A 2013 update. 2014 , 38, 12-7		5
883	Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg?. 2014 , 33, 60-3		9
882	ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type. 2014 , 21, 466-74		8
881	The role of pharmacogenetics in the treatment of chronic hepatitis C infection. 2014 , 34, 185-201		9
880	IFNL cytokines do not modulate human or murine NK cell functions. 2014 , 75, 996-1000		17
879	High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. 2014 , 20, 0936-8		2
878	Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. <i>Liver International</i> , 2014 , 34, e208-16	7.9	10
877	Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. <i>Genes and Immunity</i> , 2014 , 15, 430-2	4.4	6
876	The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 2014 , 15, 72-9		119
875	Personalized medicine and human genetic diversity. 2014 , 4, a008581		104
874	Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. 2014 , 41, 91-8		9
873	Recent advances in the anti-HCV mechanisms of interferon. 2014 , 4, 241-7		20

872	IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. <i>Journal of Medical Virology</i> , 2014 , 86, 1482-90	19.7	20
871	The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. 2014 , 3, e51		109
870	Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?. 2014 , 39, 569-78		37
869	HCV and HIV co-infection: mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 362-71	24.2	119
868	Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. 2014 , 143, 319-30		13
867	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. 2014 , 75, 822-6		11
866	The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. 2014 , 30, 72-8		17
865	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. 2014 , 110, 52-9		10
864	A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. 2014 , 20, 577-81		5
863	Novel permissive cell lines for complete propagation of hepatitis C virus. 2014 , 88, 5578-94		16
862	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. 2014 , 99, 505-10		23
861	Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. 2014 , 21, 397-404		10
860	Design and synthesis of imidazo[1,2- <i>b</i>][1,8]naphthyridine derivatives as anti-HCV agents via direct C-H arylation. 2014 , 12, 2344-8		23
859	Endogenous IFN λ in viral hepatitis patients. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 552-6	3.5	6
858	Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b. 2014 , 11, 148		1
857	Antiviral treatment of hepatitis C. 2014 , 348, g3308		154
856	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 2014 , 61, 1238-46		100
855	Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. 2014 , 15, 349-70		104

854	Hepatitis C virus and interferon type III (interferon- β /interleukin-28B and interferon- λ): genetic basis of susceptibility to infection and response to antiviral treatment. 2014 , 20, 1237-45	12
853	Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. 2014 , 21, 19-24	19
852	Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a + ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. 2014 , 49, 492-501	5
851	The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. 2014 , 33, 2025-33	8
850	IFN- λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN- β genotype and with nonresponsiveness to IFN- β therapies. 2014 , 211, 857-68	54
849	IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. 2014 , 192, 2770-7	17
848	Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 Δ allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. 2014 , 59, 274-5	10
847	A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon- β and ribavirin therapy. 2014 , 20, 320-4	4
846	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. 2014 , 44, E38-E44	6
845	Immune control and failure in HCV infection--tipping the balance. 2014 , 96, 535-48	33
844	Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma. 2014 , 35, 8757-63	10
843	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. 2014 , 105, 135-42	13
842	rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report. 2014 , 46, 2426-9	1
841	[The value of genetics in the era of hepatitis C triple therapy]. 2014 , 37, 427-37	2
840	Inhibition of protein and cell attachment on materials generated from N-(2-hydroxypropyl) acrylamide. 2014 , 15, 3259-66	27
839	Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 479-97 3-5	12
838	Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. 2014 , 29, 1728-35	3
837	Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3. <i>Journal of Medical Virology</i> , 2014 , 86, 707-12 19-7	11

836	Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. 2014 , 59, 1225-8	17
835	Hepatitis B and C in African Americans: current status and continued challenges. 2014 , 12, 738-48	32
834	Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. 2014 , 12, 334-40	40
833	Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis. 2014 , 21, 163-70	6
832	Hepatitis C virus 5' untranslated region variability correlates with treatment outcome. 2014 , 21, 551-9	4
831	Genetic polymorphisms of the IFN γ genes are associated with biochemical features in Han Chinese with HCV infection from Yunnan Province, China. 2014 , 21, 161-5	15
830	Advances in individualized and regenerative medicine. 2014 , 59, 7-12	6
829	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. 2014 , 90, 119-26	20
828	Role of genetics in diagnosis and therapy of acquired liver disease. 2014 , 37, 15-34	5
827	Validation of TaqMan Δ SNP genotyping specificity for rs12979860 of IL-28B: modeling primer specificity in vitro. 2014 , 203, 39-47	2
826	No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. 2014 , 46, 348-52	12
825	Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. 2014 , 12, 327-333.e1	8
824	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. 2014 , 15, 1337-49	21
823	Peginterferon α in the treatment of chronic hepatitis B. 2014 , 14, 995-1006	13
822	Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. 2014 , 17, 65-76	26
821	Pushing to a cure by harnessing innate immunity against hepatitis C virus. 2014 , 108, 156-64	7
820	Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. 2014 , 61, 770-6	9
819	Interferon- γ in the context of viral infections: production, response and therapeutic implications. 2014 , 6, 563-74	79

818	Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. 2014 , 14, 6-13	20
817	[Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C]. 2014 , 103, 625-9	
816	Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. 2014 , 6, 61-77	23
815	Genotype F of hepatitis B: response to interferon. 2015 , 20, 453-6	2
814	Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. 2015 , 20, 185-92	6
813	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. 2014 , 9, 2051-67	16
812	Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. 2014 , 109, 345-51	4
811	Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections. 2014 , 1, e000010	2
810	Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon- α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group. 2014 , 33, 1652-6	
809	IL28B genotyping and treatment of HCV infected subjects. 2014 , 8, 445-452	
808	Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. 2015 , 20, 407-13	
807	Genomic medicine: health care issues and the unresolved ethical and social dilemmas. 2014 , 21, 548-53	4
806	Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients. 2014 , 97 Suppl 8, S47-53	3
805	Correlation between the genetic variations in interleukin 28B and chronic hepatitis C virus genotypes in the Chinese population. 2014 , 10, 1037-45	1
804	IFNL3 expression and response to treatment: behind the HCV tricks. 2014 , 61, 944-6	
803	Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. 2015 , 89 Suppl 2, 42-6	7
802	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. 2015 , 45, E115-21	35
801	Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. <i>Liver International</i> , 2015 , 35, 1923-33	7.9 24

800	The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. 2015 , 86, 267-75	9
799	Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. 2015 , 54, 107-17	16
798	Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders. 2015 , 54, 273-9	2
797	An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin. 2015 , 54, 2173-7	
796	IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. 2015 , 5, 16037	37
795	PharmGKB summary: peginterferon- α pathway. 2015 , 25, 465-74	
794	Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. 2016 , 21, 97-106	6
793	Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. 2015 , 5, 17030	23
792	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. 2015 , 4, 357	7
791	Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. <i>Journal of Medical Virology</i> , 2015 , 87, 1361-7	19.7
790	The birth and potential death of IL28B genotyping for hepatitis C therapy. 2015 , 12, 55-57	2
789	The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome. 2015 , 15, 556	9
788	Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon- α and ribavirin therapy. 2015 , 12, 220	3
787	Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. 2015 , 123, 765-71	5
786	IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. 2015 , 20, 805-14	2
785	Advances in drug development for hepatitis C. 2015 , 65, 239-244	2
784	Progress of antiviral therapy for hepatitis C virus infection. 2015 , 30, 25-33	
783	Spontaneous negativation of serum hepatitis C virus RNA in type C chronic liver disease: A retrospective study. 2015 , 56, 414-421	1

782	[Clinical Implication of Insulin Resistance in Chronic Hepatitis C Patients]. 2015 , 89, 1-9		0
781	Randomized trial of low-dose peginterferon β -2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015 , 87, 2082-9	19.7	
780	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , 2015 , 35, 2275-84	7.9	
779	Randomized study comparing vitamin D3 and 1 β -Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C. 2015 , 30, 1384-90		12
778	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. 2015 , 62, 1375-87		19
777	IFN- γ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. <i>Journal of Medical Virology</i> , 2015 , 87, 1702-15	19.7	7
776	The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. 2015 , 42, 296-306		11
775	Association of HLA-DP/DQ, STAT4 and IL-28B variants with HBV viral clearance in Tibetans and Uygurs in China. <i>Liver International</i> , 2015 , 35, 886-96	7.9	22
774	Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. 2015 , 22, 992-1001		5
773	Recent advances in management of the HIV/HCV coinfecting patient. 2015 , 10, 981-997		4
772	Utilization of a Duplex HybProbe Real-Time PCR to Detect and Estimate IL-28B Polymorphisms Prevalence among HIV/HCV Co-infected Patients in Hong Kong. 2015 , 04,		
771	IL28B is associated with outcomes of chronic HBV infection. 2015 , 56, 625-33		8
770	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11088-111	5.6	59
769	Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil. 2015 , 7, 71-9		3
768	Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions. 2015 , 16, 20576-94		11
767	Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. 2015 , 16, 22223-42		4
766	Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. 2015 , 8, 337-50		4
765	NK cell function and receptor diversity in the context of HCV infection. 2015 , 6, 1061		23

764	IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. 2015 , 10, e0117397	10
763	Prevalence of Thymine-Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. 2015 , 10, e0125400	7
762	Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. 2015 , 10, e0125664	2
761	Substitution in Amino Acid 70 of Hepatitis C Virus Core Protein Changes the Adipokine Profile via Toll-Like Receptor 2/4 Signaling. 2015 , 10, e0131346	11
760	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. 2015 , 10, e0137351	19
759	Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection. 2015 , 10, e0137365	5
758	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. 2015 , 10, e0138827	5
757	IFN- λ Inhibits MiR-122 Transcription through a Stat3-HNF4 α Inflammatory Feedback Loop in an IFN- λ Resistant HCV Cell Culture System. 2015 , 10, e0141655	10
756	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. 2015 , 10, e0142539	7
755	The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. 2015 , 10, e0130899	7
754	IFN- λ A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. 2015 , 2015, 796461	7
753	Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. 2015 , 2015, 768470	17
752	An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. 2015 , 29, 19-34	59
751	EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection. 2015 , 2015, 716315	14
750	A case of chronic hepatitis C, genotype 3b relapsed after interferon monotherapy, treated with pegylated interferon plus ribavirin and achieved sustained virological response. 2015 , 56, 88-95	
749	Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. <i>Annals of Hepatology</i> , 2015 , 14, 28-35	3.1 3
748	IFNL3 polymorphisms and HCV infection in patients with beta thalassemia. <i>Annals of Hepatology</i> , 2015 , 14, 389-395	3.1 5
747	Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. 2015 , 27, 55-64	2

746	Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT). 2015 , 45, 1091-9		4
745	Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3786-800	5.6	18
744	HLA-B alleles B*15:01 and B*15:02: opposite association with hepatitis C virus infection in Chinese voluntary blood donors. 2015 , 58, 80-7		10
743	TGF- β polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. 2015 , 14, 4461-8		19
742	A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population. 2015 , 15, 58		6
741	Design, synthesis, and Gaussia luciferase Assay of triorganotin(IV)-based HCV inhibitors. 2015 , 24, 1635-1643		3
740	Influence of host resistance on viral adaptation: hepatitis C virus as a case study. 2015 , 8, 63-74		4
739	Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. <i>Genes and Immunity</i> , 2015 , 16, 321-9	4.4	21
738	Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. 2015 , 74, 268-72		3
737	Hepatitis C virus genetic variability and evolution. 2015 , 7, 831-45		69
736	Impact of Donor and Recipient Single Nucleotide Polymorphisms in Living Liver Donor Transplantation for Hepatitis C. 2015 , 47, 2916-9		2
735	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. 2015 , 90, 288-94		38
734	Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. 2015 , 94, e1409		
733	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. 2015 , 98, 283-94		9
732	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. 2015 , 47, 470-519		46
731	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. 2015 , 99-127		4
730	Effect of IL28B genotype on hepatitis B and C virus infection. 2015 , 14, 50-5		17
729	Impact of interleukin-28B polymorphism on HCV-1 infected patients treated with response-guided therapy. 2015 , 2, 25-32		1

728	Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. 2015 , 26, 121-31		35
727	IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2015 , 87, 814-20	19.7	10
726	Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. <i>Journal of Medical Virology</i> , 2015 , 87, 609-18	19.7	5
725	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. 2015 , 60, 2030-7		3
724	Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. 2015 , 30, 1183-9		67
723	Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. 2015 , 31, 161-8		4
722	Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. <i>Archives of Virology</i> , 2015 , 160, 1105-12	2.6	6
721	Type I interferons in infectious disease. 2015 , 15, 87-103		1131
720	Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus. 2015 , 42, 673-9		
719	Impaired induction of interleukin 28B and expression of interferon λ associated with nonresponse to interferon-based therapy in chronic hepatitis C. 2015 , 30, 1075-84		14
718	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. <i>Liver International</i> , 2015 , 35, 448-54	7.9	6
717	Interferon- λ is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. 2015 , 476, 334-340		30
716	Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. 2015 , 15, 422-9		22
715	Innate and adaptive genetic pathways in HCV infection. 2015 , 85, 231-40		11
714	The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. 2015 , 16, 293-8		14
713	Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. 2015 , 123, 342-9		9
712	The Role of Interferon- λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. 2015 , 7, 231-42		22
711	Activation of Type I and Type III Interferons in Chronic Hepatitis C. 2015 , 7, 251-259		13

710	A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. 2015 , 50, 1069-77		5
709	MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection. <i>Biomedical Reports</i> , 2015 , 3, 247-253	1.8	2
708	IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. 2015 , 6, 153		3
707	Transcriptome analysis reveals a classical interferon signature induced by IFN α in human primary cells. <i>Genes and Immunity</i> , 2015 , 16, 414-21	4.4	3 ¹
706	Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection. 2015 , 16, 3213-25		1
705	Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aborigines in Canadian HIV-hepatitis C co-infected individuals. 2015 , 16, 6496-512		5
704	Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. 2015 , 69, 184-9		4
703	Advanced molecular surveillance of hepatitis C virus. <i>Viruses</i> , 2015 , 7, 1153-88	6.2	9
702	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. 2015 , 63, 1103-10		52
701	Interferon- α Immune Functions at Barrier Surfaces and Beyond. 2015 , 43, 15-28		280
700	Guarding the frontiers: the biology of type III interferons. 2015 , 16, 802-9		212
699	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. 2015 , 13, 2071-87.e16		75
698	P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy. 2015 , 2, 197-210		1
697	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. 2015 , 31, 271-7		3
696	Natural History of Hepatitis C. 2015 , 120-130		
695	The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. <i>Archives of Virology</i> , 2015 , 160, 1043-54	2.6	3
694	Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study. 2015 , 71, 307-14		4
693	Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis. 2015 , 9, 67-75		4

692	ITPA gene variant may protect against anemia induced during pegylated interferon Alfa and Ribavirin combination treatment in Ukrainian patients with chronic hepatitis C. 2015 , 49, 109-112		
691	Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon- β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Journal of Interferon and Cytokine Research</i> , 2015 , 35, 613-20	3.5	5
690	The correlation between hepatitis C core antigen and hepatitis C virus RNA levels with respect to human immunodeficiency virus status, hepatitis C virus genotype and interferon-lambda-4 polymorphism. 2015 , 58, 73-9		8
689	Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. <i>Archives of Virology</i> , 2015 , 160, 1741-50	2.6	9
688	Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2015 , 35, 846-53	7.9	8
687	Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. 2015 , 30, 91-7		27
686	Prevalence of abnormal glycometabolism in treatment-naive patients with hepatitis C virus infection in a Chinese Han population. 2015 , 30, 1049-56		3
685	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. 2015 , 9, 486-507		13
684	Interferon- β rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. 2015 , 6, 6422		127
683	Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. <i>Liver International</i> , 2015 , 35, 2256-64	7.9	9
682	Insights into antiviral innate immunity revealed by studying hepatitis C virus. 2015 , 74, 190-7		5
681	IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. 2015 , 39, 576-83		14
680	Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. 2015 , 61, 1192-204		3
679	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. 2015 , 63, 554-63		20
678	Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. 2015 , 220, 1-4		9
677	Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1. 2015 , 39, 711-7		4
676	Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF- β , With Severity of Disease Caused by Andes Virus. 2015 , 61, e62-9		15
675	Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. 2015 , 37, 1180-4		1

674	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. 2015 , 16, 1179-88		15
673	Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. 2015 , 30, 178-83		5
672	Hepatitis C virus vaccine development: old challenges and new opportunities. 2015 , 2, 285-295		22
671	Natural History of Hepatitis C. 2015 , 44, 717-34		121
670	Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. <i>Archives of Virology</i> , 2015 , 160, 2833-7	2.6	12
669	Immunopathogenesis of Hepatitis C Virus Infection. 2015 , 44, 735-60		9
668	Spontaneous clearance of HCV accompanying hepatitis after liver transplantation. 2015 , 8, 323-9		5
667	A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance. 2015 , 10, 365-76		20
666	Translating the Untranslated Region. 2015 , 195, 2963-71		59
665	Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. 2015 , 39, 705-10		2
664	IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. 2015 , 67, 260-6		3
663	Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. 2015 , 134, 279-89		8
662	Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. <i>Liver International</i> , 2015 , 35, 482-8	7.9	4
661	Association of serum IFN- β with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. 2015 , 50, 894-902		22
660	Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. 2015 , 211, 906-14		50
659	Perceptions of genetic testing and genomic medicine among drug users. 2015 , 26, 100-6		7
658	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 2015 , 22, 318-27		19
657	T cell responses in hepatitis C virus infection: historical overview and goals for future research. 2015 , 114, 96-105		34

656	IFN- β -mediated IL-12 production in macrophages induces IFN- γ production in human NK cells. 2015 , 45, 250-9		50
655	A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. 2015 , 13, 1017-24		43
654	Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype. 2015 , 45, 387-96		
653	Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. <i>Liver International</i> , 2015 , 35, 473-81	7.9	18
652	BDCA3(+)/CLEC9A(+) human dendritic cell function and development. 2015 , 41, 39-48		39
651	Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. 2015 , 114, 652-8		2
650	Respiratory proteomics: from descriptive studies to personalized medicine. 2015 , 14, 38-50		21
649	IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. 2015 , 16, 90-7		13
648	Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3. <i>Journal of Interferon and Cytokine Research</i> , 2015 , 35, 313-6	3.5	
647	Increased concentration of interferon lambda-3, interferon beta and interleukin-10 in the cerebrospinal fluid of patients with tick-borne encephalitis. 2015 , 71, 125-31		15
646	Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. 2015 , 9, 375-85		14
645	Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. 2015 , 61, 460-70		28
644	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. 2015 , 61, 712-21		114
643	Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. 2015 , 55, 63-72		5
642	Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. 2015 , 9, 21-30		4
641	Homozygosity for HLA group 2 alleles predicts treatment failure with interferon- β and ribavirin in chronic hepatitis C virus genotype 1 infection. <i>Journal of Interferon and Cytokine Research</i> , 2015 , 35, 126-35		4
640	Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy. 2015 , 45, 88-96		12
639	Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. 2015 , 45, 837-45		15

638	Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. 2016 , 34, 335-41		3
637	Hepatitis C Virus. 2016 , 351-361		
636	Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. 2016 , 8, 1116-8		1
635	Interferon lambda 4 (IFNL4) gene polymorphism is associated with spontaneous clearance of HCV in HIV-1 positive patients. 2016 , 39, 374-9		6
634	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. 2016 , 181, 1375-1381		1
633	Pharmacogenomics for Infectious Diseases. 2016 , 05,		3
632	Prevalence of Hepatitis C among Egyptian Children with Sickle Cell Disease and the Role of IL28b Gene Polymorphisms in Spontaneous Viral Clearance. 2016 , 8, e2016007		4
631	Natural killer cells in hepatitis C: Current progress. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1449-60	5.6	34
630	Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon- α /ribavirin therapy in chronic hepatitis C genotype 4 patients. 2016 ,		2
629	The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis. <i>Hepatitis Monthly</i> , 2016 , 16, e37534	1.8	4
628	Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. 2016 , 2016, 3894816		5
627	Type III Interferons in Hepatitis C Virus Infection. 2016 , 7, 628		23
626	genotype is associated with cirrhosis or transition to cirrhosis in treatment-naïve patients with chronic HCV genotype 1 infection: the international observational Gen-C study. 2016 , 5, 1990		9
625	Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable polymorphism. 2017 , 5, 208-212		4
624	Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. 2016 , 11, e0147007		1
623	IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C. 2016 , 11, e0162068		4
622	Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a + Ribavirin for Chronic Hepatitis C. 2016 , 62, 93-6		13
621	Pharmacogenetics of ribavirin-induced anemia in HCV patients. 2016 , 17, 925-41		16

620	Host genetic variants influencing the clinical course of hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2016 , 88, 185-95	19.7	26
619	Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. <i>Journal of Medical Virology</i> , 2016 , 88, 481-6	19.7	5
618	Immune responses and immunopathology in acute and chronic viral hepatitis. 2016 , 16, 509-23		176
617	Genetic variation in STAT4 predicts response to interferon- β therapy for hepatitis B e antigen-positive chronic hepatitis B. 2016 , 63, 1102-11		20
616	Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. <i>Journal of Medical Virology</i> , 2016 , 88, 506-11	19.7	18
615	Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. <i>Journal of Medical Virology</i> , 2016 , 88, 1776-84	19.7	2
614	Hepatitis C-A clinical review. <i>Journal of Medical Virology</i> , 2016 , 88, 1844-55	19.7	27
613	Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. 2016 , 46, 450-8		15
612	Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. 2016 , 31, 1628-37		8
611	A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. 2016 , 23, 427-38		24
610	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016 , 36, 198-204	7.9	12
609	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. 2016 , 6, 22995		3
608	Molecular Detection and Characterization of Hepatitis C Virus. 2016 , 430-448		
607	The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. 2016 , 144, 1634-40		8
606	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. 2017 , 64, 621-628		26
605	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. 2016 , 63, 63-73		37
604	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701		60
603	The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. 2016 , 291, 12294-309		20

602	Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus. 2016 , 7, 83-9		17
601	IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. 2016 , 77, 79-87		9
600	Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. 2016 , 493, 136-41		7
599	APASL consensus statements and recommendation on treatment of hepatitis C. 2016 , 10, 702-26		155
598	Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study. 2016 , 128, 432-8		3
597	Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. 2016 , 113, 10678-83		21
596	Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients. <i>Journal of Interferon and Cytokine Research</i> , 2016 , 36, 698-705	3.5	15
595	Targeting IFN- β therapeutic implications. 2016 , 20, 1425-1432		12
594	Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. 2016 , 88, 29-36		1
593	Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. 2016 , 20, 1-10		32
592	Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. 2016 , 44, 554-67		62
591	Top-cited articles in digestive system disease from 1950 to 2013. 2016 , 31, 107-11		28
590	Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. 2016 , 113, 10388-93		65
589	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. <i>Archives of Virology</i> , 2016 , 161, 3161-9	2.6	21
588	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. 2016 , 17, 1587-94		7
587	Host - hepatitis C viral interactions: The role of genetics. 2016 , 65, S22-S32		42
586	Antibodies to HBV surface antigen in relation to interferon- β in hemodialysis patients. 2016 , 34, 4866-4874		5
585	Immune Cell Profiling of IFN- β Response Shows pDCs Express Highest Level of IFN- β 1 and Are Directly Responsive via the JAK-STAT Pathway. <i>Journal of Interferon and Cytokine Research</i> , 2016 , 36, 671-680	3.5	35

584	polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients. 2016 , 50, 330-333		1
583	Role of Some Predominant Host Immunomodulators' Single Nucleotide Polymorphisms in Severity of Hepatitis B Virus and Hepatitis C Virus Infection. 2016 , 29, 536-545		6
582	Genetic variations of the NPC1L1 gene associated with hepatitis C virus (HCV) infection and biochemical characteristics of HCV patients in China. 2016 , 53, 6-11		7
581	Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis. 2016 , 53, 52-58		7
580	Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 2016 , 22, 1475-1481		26
579	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. 2016 , 225-241		
578	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. 2016 , 115, 953-960		5
577	Hepatitis C Virus II. 2016 ,		1
576	Interferon lambda 4 expression is suppressed by the host during viral infection. 2016 , 213, 2539-2552		43
575	Hepatitis C Virus I. 2016 ,		2
574	A case of hepatitis C virus-associated mixed cryoglobulinemia treated with direct-acting antivirals. 2016 , 57, 405-411		
573	Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems. 2016 , 6, 30939		16
572	A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. 2016 , 95, e5327		7
571	Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections. <i>Genes and Immunity</i> , 2016 , 17, 265-75	4.4	13
570	Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?. <i>Journal of Interferon and Cytokine Research</i> , 2016 , 36, 204-14	3.5	1
569	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016 , 17, 328-34	4.4	8
568	Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. 2016 , 5, 518		4
567	Responder Interferon [Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. 2016 , 214, 80-6		9

566	Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?. 2016 , 11, 23		15
565	Real-world effectiveness of peginterferon α -2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. 2016 , 35, 597-609		0
564	Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2016 , 88, 268-74	19.7	9
563	Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy. 2016 , 46, 1162-1167		2
562	Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. 2016 , 46, 1311-1320		7
561	Impact of host genetic polymorphisms on vaccine induced antibody response. 2016 , 12, 907-15		34
560	A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. 2016 , 61, 301-5		11
559	Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. <i>Archives of Virology</i> , 2016 , 161, 1477-84	2.6	10
558	Pharmacogenetic Predictors of Response. 2016 , 882, 191-215		3
557	Novel Biomarkers in the Continuum of Breast Cancer. 2016 ,		9
556	Host-virus interactions in hepatitis B and hepatitis C infection. 2016 , 51, 409-20		21
555	Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon- α Expression. 2016 , 186, 938-51		10
554	IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. 2016 , 39, 132-140		7
553	Personalized Medicine in Respiratory Disease: Role of Proteomics. 2016 , 102, 115-46		16
552	Photosensitizer-loaded bubble-generating mineralized nanoparticles for ultrasound imaging and photodynamic therapy. 2016 , 4, 1219-1227		30
551	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. 2016 , 48, 650-5		6
550	Design, synthesis, structure information and biochemical activity of new floro substituted organotin(IV) carboxylates. 2016 , 154, 99-107		3
549	Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. 2016 , 51, 260-70		17

548	Endogenously produced TNF- β contributes to the expression of CXCL10/IP-10 in IFN- β -activated plasmacytoid dendritic cells. 2016 , 99, 107-19	18	
547	Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. 2016 , 16, 18-29	9	
546	The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. 2016 , 51, 63-70	13	
545	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN β . 2017 , 66, 724-735	46	
544	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. 2017 , 17, 312-318	19	
543	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. 2017 , 19, 876-882	1	
542	Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. 2017 , 17, 225-232	7	
541	Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. 2017 , 17, 217-223	6	
540	IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. 2017 , 47, E5-E13	4	
539	Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. 2017 , 32, 1495-1502	9	
538	Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. 2017 , 15, 937-944.e5	17	
537	Personalized medicine: Genetic risk prediction of drug response. 2017 , 175, 75-90	26	
536	A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. 2017 , 445, 15-22	2	
535	New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. 2017 , 52, 855-867	9	
534	Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. 2017 , 152, 1383-1394	76	
533	A systematic review and meta-analysis of HCV clearance. <i>Liver International</i> , 2017 , 37, 1431-1445	7.9	24
532	Genetic variants in interferon- λ influences HCV clearance in Chinese Han population. 2017 , 7, 42408	4	
531	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017 , 49, 666-673	36.3	81

530	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
529	Interferon β gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. 2017 , 57, 1376-1384		2
528	Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2017 , 37, 278-286	3.5	1
527	Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. 2017 , 67, 933-939		132
526	Methods to analyze big data in pharmacogenomics research. 2017 , 18, 807-820		8
525	Zinc is a potent and specific inhibitor of IFN- β signalling. 2017 , 8, 15245		38
524	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. 2017 , 7, 3718		13
523	IFN- α potently blocks IFN- β signalling by ISG15 and USP18 in hepatitis C virus infection. 2017 , 7, 3821		17
522	Genetic variation in interleukin 28B rs8099917 and response to antiviral therapy in Moroccan patients with chronic hepatitis C. 2017 , 8, 84-87		
521	Evaluation of three techniques for detection of IL28B SNP: A prognostic tool for HCV treatment outcome. 2017 , 18, 404-409		2
520	Genetik metabolischer und viraler Lebererkrankungen. 2017 , 12, 16-31		0
519	Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2017 , 89, 1574-1583	19.7	3
518	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. 2017 , 67, 237-245		20
517	Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. 2017 , 10, 201-207		15
516	SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. <i>Journal of Medical Virology</i> , 2017 , 89, 1620-1628	19.7	18
515	Tolerability and efficacy of pegylated consensus interferon- β in the treatment of chronic hepatitis C. 2017 , 13, 9-16		2
514	Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2017 , 89, 1241-1247	19.7	7
513	Epigenetic analysis of the IFN β gene identifies a novel marker for response to therapy in HCV-infected subjects. 2017 , 24, 397-403		1

512	Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. 2017 , 11, 161-170		24
511	A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C. 2017 , 48, 51-56		6
510	IFN- λ Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. 2017 , 199, 3808-3820		42
509	Hepatitis C and the Impact of Host Genetics. 2017 , 19, 805-808		
508	Serum IFN- β Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. 2017 , 35, 531-540		1
507	The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis. 2017 , 58, 172-189		21
506	Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population. 2017 , 99, 297-304		7
505	Human Genetic Determinants of Viral Diseases. 2017 , 51, 241-263		68
504	Discovery of Variants Underlying Host Susceptibility to Virus Infection Using Whole-Exome Sequencing. 2017 , 1656, 209-227		
503	A functional IFN- λ -generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma. 2017 , 7, 10500		5
502	Human Virology in Latin America. 2017 ,		3
501	Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon- β -Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. <i>Journal of Interferon and Cytokine Research</i> , 2017 , 37, 216-222	3.5	6
500	High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan. 2017 , 33, 510-515		1
499	Interferon lambda 4 rs368234815 TT> λ variant is associated with liver damage in patients with nonalcoholic fatty liver disease. 2017 , 66, 1885-1893		59
498	The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. 2017 , 32, 1139-1146		31
497	Human genetics ability to predict the risk of suffering an infectious disease. 2017 , 149, 32-35		
496	Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. 2017 , 96, e6128		30
495	Innate Antiviral Immunity. 2017 ,		3

- 494 Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. **2017**, 16, 317-325 1
- 493 Association of interleukin-28B polymorphisms with platelet count and liver function recovery after liver transplant. **2017**, 96, e8219 3
- 492 Human genetics ability to predict the risk of suffering an infectious disease. **2017**, 149, 32-35
- 491 The association between interleukin-28B gene polymorphisms as a potential biomarker and the risk of chronic Periodontitis in an Iranian population. **2017**, 13, 16 6
- 490 Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients. **2017**, 17, 54 11
- 489 SVR Rates of HCV-infected population under PEG-IFN- α /R treatment in Northwest China. **2017**, 14, 62 7
- 488 Hepatitis C Virus Treatment. **2017**,
- 487 Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. **2017**, 17, 112-120 19
- 486 Incidence and Characteristics of Naturally Occurring Drug-Resistant Hepatitis C Virus Strains. **2017**, 45-50
- 485 Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. **2017**, 30, 23-42 7
- 484 Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. *Journal of Medical Virology*, **2017**, 89, 388-396 19.7 9
- 483 Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach. **2017**, 467, 59-69 4
- 482 Gadoteric Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study. **2017**, 57, 369-375 5
- 481 A global perspective on hepatitis B-related single nucleotide polymorphisms and evolution during human migration. **2017**, 1, 1005-1013 3
- 480 Effect of switching of previous nucleos(t)ide analogues to Tenofovir on Hepatitis B surface antigen levels. **2017**, 58, 354-356
- 479 Viral and host factors associated with outcomes of hepatitis C virus infection (Review). **2017**, 15, 2909-2924 15
- 478 Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C. **2017**,
- 477 Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy. **2017**, 35, 580-584 2

476	Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil. 2017 , 50, 470-477	4
475	Association of TNF- β and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. 2017 , 3, 16-22	1
474	Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. 2017 , 28, 80-86	1
473	Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. 2017 , 5,	29
472	Interferon Lambda: Modulating Immunity in Infectious Diseases. 2017 , 8, 119	84
471	IFN- β Inhibits Drug-Resistant HIV Infection of Macrophages. 2017 , 8, 210	9
470	Interferon- β and Plasmacytoid Dendritic Cells: A Close Relationship. 2017 , 8, 1015	13
469	Interferon Lambda Genetics and Biology in Regulation of Viral Control. 2017 , 8, 1707	66
468	Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. 2017 , 2017, 2093847	2
467	Circulating Interferon-3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. 2017 , 2017, 3713025	4
466	The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. 2017 , 2017, 7232361	17
465	Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases. 2017 , 93, 657-676	4
464	Viral Hepatitis. 2017 , 317-340	0
463	Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. 2017 , 12, e0180927	8
462	Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. 2017 , 12, e0182204	4
461	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. 2017 , 12, e0182710	32
460	Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. 2017 , 12, e0186255	10
459	CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. 2017 , 17, 169	2

458	Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. 2017 , 14, 45-52		11
457	Association of Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. 2017 , 14, 1088-1093		
456	The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation. 2017 , 3, 152-158		
455	Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. 2017 , 10, 79-91		2
454	Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. <i>Annals of Hepatology</i> , 2017 , 16, 734-741	3.1	8
453	Characterizing key nucleotide polymorphisms of hepatitis C virus-disease associations via mass-spectrometric genotyping. 2018 , 52, 441-452		
452	Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. 2018 , 97, e9782		2
451	Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma. 2018 , 60, 160-172		8
450	Human Genetic Predisposition to Diseases Caused by Viruses from Flaviviridae Family. 2018 , 52, 165-181		9
449	Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. 2018 , 100, 419-425		12
448	Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. <i>Journal of Medical Virology</i> , 2018 , 90, 919-925	19.7	7
447	Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. 2018 , 117, 1011-1018		7
446	Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. 2018 , 146, 379-385		1
445	The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. 2018 , 25, 535-542		9
444	IFN β /4 locus polymorphisms and IFN β circulating levels are associated with COPD severity and outcomes. 2018 , 18, 51		11
443	IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. 2018 , 15, 40		9
442	Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C. 2018 , 71, 51-57		19
441	Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN- λ . 2018 , 664, 168-180		7

440	Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance. 2018 , 63, 831-839		
439	Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. 2018 , 68, 859-871		15
438	Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b. 2018 , 33, 249-255		5
437	Induction of IFN- β as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. 2018 , 67, 362-371		93
436	Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. 2018 , 48, E78-E86		3
435	Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome. 2018 , 79, 70-75		5
434	Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches. 2018 , 66, 286-307		25
433	Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. <i>Archives of Virology</i> , 2018 , 163, 115-124	2.6	2
432	Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study. 2018 , 67, 651-661		24
431	Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon- α injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. 2018 , 48, 233-243		8
430	Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. 2018 , 11, 112-122		24
429	Host genetic variations associated with disease progression in chronic hepatitis C virus infection. 2018 , 48, 127-133		14
428	Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population. 2018 , 31, 249-255		2
427	Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. 2018 , 66, 376-391		7
426	Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy. <i>Annals of Hepatology</i> , 2018 , 17, 908-919	3.1	13
425	Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome. <i>Annals of Gastroenterology</i> , 2018 , 31, 593-597	2.2	1
424	Virology and Pathogenesis of Hepatitis C. 2018 , 412-427.e8		
423	Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis. 2018 ,		0

422	Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance. 2018 , 19, 215-223	3
421	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. 2018 , 32, 2759-2765	5
420	Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population. 2018 , 15, 503-510	1
419	ENHANCING POWER OF SCORE TESTS FOR REGRESSION MODELS VIA FISHER TRANSFORMATION. 2018 , 30, 37-53	1
418	Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. 2018 , 6, 1391-1400	13
417	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. 2018 , 15, 466-474	11
416	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. 2018 , 13, e0199198	4
415	Interferon- β /4 genetic variants and interferon- β serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. 2018 , 20, 193	22
414	Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. 2018 , 2018, 7685371	6
413	Synthesis and Antiviral Evaluation of TriPPPPro-AbacavirTP, TriPPPPro-CarbovirTP, and Their 1',2'-cis-Disubstituted Analogues. 2018 , 13, 1771-1778	6
412	Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. 2018 , 13, e0200221	5
411	RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus. 2018 , 115, 8197-8202	24
410	Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. 2018 , 25, 1462-1471	15
409	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. 2018 , 19, 979-995	0
408	Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. 2018 , 18, 254	1
407	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018 , 90, 1834-1840	19.7 10
406	Nearly neutral evolution in IFNL3 gene retains the immune function to detect and clear the viral infection in HCV. 2018 , 140, 107-116	
405	Pegylated Interferon- β Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. 2018 , 355, 566-572	

404	ADAR1 affects HCV infection by modulating innate immune response. 2018 , 156, 116-127		17
403	IL-15 and IFN- β signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. 2019 , 124, 154439		4
402	The role of IFN in the development of NAFLD and NASH. 2019 , 124, 154519		17
401	Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. 2019 , 25, 513.e1-513.e6		5
400	CD4 recovery is associated with genetic variation in IFN λ and IL19 genes. 2019 , 170, 104577		2
399	The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). 2019 , 317-354		0
398	Characterization of human pegivirus infection in liver transplantation recipients. <i>Journal of Medical Virology</i> , 2019 , 91, 2093-2100	19.7	7
397	haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population. 2019 , 30, 344-353		
396	Impact of Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 642-649	3.5	4
395	The IFN- β Conundrum: When a Good Interferon Goes Bad. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 636-641	3.5	11
394	Molecular prognosis in liver cirrhosis. 2019 , 413-427		
393	Genome-Wide Association Studies. 2019 ,		0
392	Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons. 2019 , 51, 451-464.e6		82
391	Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. 2019 , 12, 626		1
390	The Influence of the rs30461 Single Nucleotide Polymorphism on IFN- β Activity and Secretion. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 661-667	3.5	3
389	The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. <i>Microbial Pathogenesis</i> , 2019 , 134, 103598	3.8	1
388	Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?. 2019 , 12, 598-602		2
387	What Have We Learned From Studies of IFN- λ Variants and Hepatitis C Virus Infection?. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 618-626	3.5	2

386	IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. 2019 , 34, 2019-2027		4
385	IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period. 2019 , 21, e13124		3
384	Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection. 2019 , 9, 7943		1
383	Benefits and limitations of genome-wide association studies. 2019 , 20, 467-484		516
382	Case 15-2019: A 55-Year-Old Man with Jaundice. 2019 , 380, 1955-1963		
381	Genetics of the Human Interferon Lambda Region. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 599-608	3.5	21
380	Interferon Lambda and Liver Fibrosis. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 627-635	3.5	6
379	Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 586-591	3.5	2
378	Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?. 2019 , 8,		19
377	Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. 2019 , 54, 916-927		17
376	Hierarchical assessment of host factors influencing the spontaneous resolution of hepatitis C infection. 2019 , 50, 147-155		
375	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. 2019 , 39, 153-162		2
374	Human Pathobiochemistry. 2019 ,		
373	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. 2019 , 8,		3
372	The Impact of Translational Research in Hepatology. 2019 , 13, 29-33		1
371	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. 2019 , 10, 475		6
370	Pharmacogenomics and Infectious Diseases in Africa. 2019 , 95-127		
369	Viral hepatitis. 2019 , 155-165		

368	Association of rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. 2019 , 12, 433-439		2
367	PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. 2019 , 1-7		5
366	Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. 2019 , 156, 369-383		62
365	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. 2019 , 156, 400-417		21
364	Factors related to fatalities and clinical progression of Crimean-Congo hemorrhagic fever patients and the effects of IL 28-B gene polymorphism. <i>Archives of Virology</i> , 2019 , 164, 547-557	2.6	2
363	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. 2019 , 67, 123-133		4
362	Polymorphism in interferon β /interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. <i>Journal of Medical Virology</i> , 2019 , 91, 659-667	19.7	5
361	Pharmacogenomics. 2019 , 445-486		
360	Association of serum interferon- β levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. 2019 , 49, 500-511		5
359	Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. 2019 , 29, e2033		4
358	Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. 2019 , 11,		67
357	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 40-52	24.2	94
356	Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon. 2020 , 35, 97-103		3
355	Longitudinal evolution of vertically HIV/HCV-co-infected vs HCV-mono-infected children. 2020 , 27, 61-67		3
354	Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. 2020 , 50, 453-465		4
353	IFNL4: Notable variants and associated phenotypes. 2020 , 730, 144289		9
352	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. 2020 , 13, 463-484		5
351	Real-world efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. 2020 , 13, 1233-1238		3

350	Decreased expression of interferon-stimulated genes in B cells of patients with chronic hepatitis C during interferon-free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study. 2020 , 3, e176		1
349	The Role of Structure in the Biology of Interferon Signaling. 2020 , 11, 606489		21
348	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. 2020 , 9,		4
347	Impact of virus subtype and host genotype on large-scale RNA structure formation in the genome of hepatitis C virus. 2020 , 26, 1541-1556		6
346	Characterization of peripheral blood mononuclear cells gene expression profiles of pediatric Staphylococcus aureus persistent and non-carriers using a targeted assay. 2020 , 22, 540-549		1
345	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. 2020 , 50, 1222-1233		3
344	High-risk Allele for Herpes Labialis Severity at the IFNL3/4 Locus is Associated With Vestibular Neuritis. 2020 , 11, 570638		1
343	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. 2020 , 55, 1162-1170		2
342	Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. 2020 , 86, 104606		0
341	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020 , 21, 348-359	4.4	2
340	Genetic association study of interferon lambda 3, CD27, and human leukocyte antigen-DPB1 with dengue severity in Thailand. 2020 , 20, 948		1
339	mSphere of Influence: Interferon Ultra Is a Means To Fight Viral Disease. 2020 , 5,		
338	HCV genotypes and their determinative role in hepatitis C treatment. 2020 , 31, 235-240		11
337	Lack of Association between IFNL3 Polymorphism and Human Papillomavirus Infection and Their Progression in HIV-Infected Women Receiving Antiretroviral Treatment. 2020 , 87, 262-267		
336	B cell intrinsic expression of IFN γ receptor suppresses the acute humoral immune response to experimental blood-stage malaria. <i>Virulence</i> , 2020 , 11, 594-606	4.7	4
335	The human genetic determinism of life-threatening infectious diseases: genetic heterogeneity and physiological homogeneity?. 2020 , 139, 681-694		27
334	The STAT4 and not the IFNL3 variant is associated with hepatitis B virus clearance in a population from the Khyber Pakhtunkhwa region of Pakistan. 2020 , 21, 91-94		
333	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. 2020 , 35, 1813-1820		0

332	Poly(ethylene glycol)-interpenetrated genipin-crosslinked chitosan hydrogels: Structure, pH responsiveness, gelation kinetics, and rheology. 2020 , 137, 49259	9
331	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. 2020 , 5, 253-263	
330	Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. 2020 , 139, 855-863	5
329	Association between interferon lambda 3 rs12979860 polymorphism and clinical outcome in dengue virus-infected children. 2020 , 47, 351-358	3
328	A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFN β therapy in Chinese HBeAg-positive chronic hepatitis B patients. 2020 , 51, 469-478	3
327	Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. 2020 , 16, e1008515	22
326	Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. 2020 , 50, 817-830	6
325	The Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation. 2020 , 94,	9
324	Interferon lambda rs368234815 C/T is associated with higher CD4:CD8 T-cell ratio in treated HIV-1 infection. 2020 , 17, 13	1
323	Innate Immunity in Hepatitis C Virus Infection. 2021 , 11,	6
322	Association between IFN β Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients. 2021 , 50, 12-22	9
321	Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. 2021 , 37, 184-188	1
320	Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. 2021 , 766, 145145	29
319	Germline genetic factors influence the outcome of interferon- β therapy in polycythemia vera. 2021 , 137, 387-391	5
318	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021 , 41, 133-149	7.9 1
317	Programmed cell death-1 and interleukin-28B polymorphisms in autoimmune hepatitis. 2021 , 4, 100126	0
316	Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study. 2021 , 21, 102	1
315	Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. 2021 , 60, 3239-3243	1

314	Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection. 2021 , 13, 109-119		0
313	Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. 2021 , 3, 321-334		0
312	Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. 2021 , 259-297		
311	Acute and Chronic Hepatitis. 2021 , 819-837.e6		1
310	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. 2021 , 56, 304-311		
309	Interferon- λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. <i>Archives of Virology</i> , 2021 , 166, 1047-1056	2.6	0
308	Interleukin-28A maintains the intestinal epithelial barrier function through regulation of claudin-1. 2021 , 9, 365		0
307	Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling. 2021 , 22,		1
306	HDV Pathogenesis: Unravelling Ariadne's Thread. <i>Viruses</i> , 2021 , 13,	6.2	2
305	IL28B????????????(1)????????(GWAS). 2021 , 62, 206-208		
304	IL28B????????????(2)???. 2021 , 62, 209-211		
303	IFN- λ is associated with increased risk and earlier occurrence of several common infections in African children. <i>Genes and Immunity</i> , 2021 , 22, 44-55	4.4	2
302	Interferon- β Gene Polymorphic Variants, rs4803217 and rs12980275, Responsiveness to HBV Vaccine and Outcome of HBV and HCV Exposure in Hemodialyzed Patients. <i>Hepatitis Monthly</i> , 2021 , 21,	1.8	
301	IFN- λ therapy prevents severe gastrointestinal graft-versus-host disease. 2021 , 138, 722-737		12
300	IFNL4 rs12979860 polymorphism influences HBV DNA viral loads but not the outcome of HBV infection in Moroccan patients. 2021 , 23, 104802		1
299	Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. <i>Viruses</i> , 2021 , 13,	6.2	2
298	Functional genetic variants of the IFN- β (IL28B) gene and transcription factor interactions on its promoter. 2021 , 142, 155491		0
297	Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. <i>Archives of Virology</i> , 2021 , 166, 2469-2478	2.6	0

296	A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. <i>Liver International</i> , 2021 ,	7.9	1
295	Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. 2021 , 11, 656393		1
294	Transmission dynamic of stochastic hepatitis C model by spectral collocation method. 2021 , 1-15		2
293	RNA regulatory mechanisms that control antiviral innate immunity. 2021 , 304, 77-96		5
292	Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients. 2021 ,		1
291	Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. 2021 , 12, 4882		2
290	Intracellular Accumulation of IFN- λ Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects. 2021 , 12, 692263		1
289	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. 2021 , 10,		2
288	Respiratory syncytial virus-specific immunoglobulin G (IgG) concentrations associate with environmental and genetic factors: the Factors Influencing Pediatric Asthma Study.		
287	Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. 2021 , 29, 100909		
286	Human host genetics and susceptibility to ZIKV infection. 2021 , 95, 105066		2
285	Nucleic acid biomarker technology for cancer immunotherapy. 2022 , 331-356		
284	Interferons. 2021 , 447-452		0
283	Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. 2021 , 10,		5
282	Interferon signaling. 214-225		1
281	Antiviral Targets in HCV. 2012 , 203-225		1
280	Natural History of Chronic Hepatitis C. 2016 , 3-55		1
279	Pharmacogenomics of Viral Diseases. 2013 , 637-676		1

278	Replication of Hepatitis C Virus. 2012 , 97-110	1
277	Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. 2021 , 22,	4
276	Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase. 2015 , 96, 3236-3242	17
275	Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?. 2016 , 97, 2592-2598	2
274	Experimental models to study the immunobiology of hepatitis C virus. 2011 , 92, 477-93	17
273	IFN- γ is associated with increased risk and earlier occurrence of gastrointestinal, respiratory and malarial infections in Malian children.	1
272	Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus.	1
271	PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. 2018 , 48, E335-E339	5
270	Hepatitis C Virus. 1599-1616	1
269	A human PSMB11 variant affects thymoproteasome processing and CD8+ T cell production. 2017 , 2,	6
268	There's a goat behind door number 3: from Monty Hall to medicine. 2011 , 121, 3819-21	3
267	Association between IL28B Polymorphisms and Outcomes of Hepatitis B Virus Infection: A meta-analysis. 2020 , 21, 88	7
266	Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. 2011 , 17, CR687-91	3
265	Recent advances in understanding hepatitis C. 2016 , 5,	12
264	Role of genetic polymorphisms in hepatitis C virus chronic infection. 2015 , 3, 807-22	12
263	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. 2011 , 8, e1001092	93
262	ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver. 2011 , 6, e14697	15
261	Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. 2010 , 5, e15200	68

260	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. 2011 , 6, e17232	120
259	Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. 2011 , 6, e19799	13
258	An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. 2011 , 6, e20904	23
257	Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. 2011 , 6, e21854	15
256	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. 2011 , 6, e24514	8
255	Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. 2011 , 6, e24907	77
254	Highly parallel and short-acting amplification with locus-specific primers to detect single nucleotide polymorphisms by the DigiTag2 assay. 2012 , 7, e29967	11
253	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. 2012 , 7, e30513	16
252	Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. 2012 , 7, e32028	30
251	Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots. 2012 , 7, e33000	8
250	Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. 2012 , 7, e38578	30
249	A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. 2012 , 7, e39027	50
248	Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfecting patients: significant associations with IL28B and SOCS3 gene variants. 2012 , 7, e47725	9
247	Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. 2012 , 7, e52048	22
246	IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. 2013 , 8, e58071	23
245	Interferon-lambda3 (IFN- λ 3) and its cognate receptor subunits in tree shrews (<i>Tupaia belangeri</i>): genomic sequence retrieval, molecular identification and expression analysis. 2013 , 8, e60048	7
244	1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial. 2013 , 8, e63672	21
243	Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. 2013 , 8, e66872	5

242	Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. 2013 , 8, e77911	11
241	KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. 2013 , 8, e83381	15
240	Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. 2014 , 9, e90462	3
239	Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. 2014 , 9, e91822	28
238	IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan. 2014 , 9, e93011	8
237	IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda. 2014 , 9, e93434	8
236	An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. 2014 , 9, e104202	6
235	Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. 2014 , 9, e112592	17
234	Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C. 2015 , 10, e0118000	8
233	Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. 2015 , 10, e0119172	10
232	Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. 2015 , 10, e0136227	12
231	24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. 2015 , 10, e0140853	2
230	Hepatic Interferon-β (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C. 2015 , 10, e0143783	2
229	Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. 2016 , 11, e0146258	23
228	Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey. 2016 , 11, e0149362	28
227	A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. 2016 , 11, e0156850	3
226	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. 2016 , 11, e0164418	7
225	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. 2017 , 12, e0170667	2

224	Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. 2013 , 1, 116-24	7
223	Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. 2014 , 2, 1-6	9
222	Genome-Wide Association Study Reveals Host Genetic Factors for Liver Diseases. 2013 , 1, 45-50	4
221	Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. 2016 , 4, 26-31	1
220	Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment. 2014 , 7, 123-130	2
219	Genetic predictors of the response to the treatment of hepatitis C virus infection. 2015 , 15, 55-9	4
218	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. 2016 , 7, 61325-61335	6
217	Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. 2018 , 9, 4188-4199	1
216	Genetic Polymorphisms within Interferon- λ Region and Interferon- β in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. 2019 , 26, 4832-4851	2
215	Innate and Adaptive Immune Responses in Chronic HCV Infection. 2017 , 18, 826-843	31
214	Relationship between SNPs in the IL28B region and amino acid substitutions in HCV core region in Japanese patients with chronic hepatitis C. 2010 , 51, 322-323	3
213	The efficacy of ezetimibe add-on with combination peginterferon plus ribavirin therapy in patients with chronic hepatitis C. 2010 , 51, 607-614	1
212	Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2. 2011 , 52, 236-243	3
211	Treatment Guidelines of Hepatitis C. 2012 , 53, 355-395	2
210	Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. 2012 , 18, 360-7	12
209	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. 2013 , 19, 60-9	5
208	No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. 2014 , 20, 177-84	4
207	KASL clinical practice guidelines: management of hepatitis C. 2014 , 20, 89-136	30

206	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139		58
205	Recent trends in the treatment of chronic hepatitis C. 2012 , 18, 22-8		12
204	Genetic screening for metabolic and age-related complications in HIV-infected persons. 2010 , 2, 83		6
203	IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3636-9	5.6	41
202	Peginterferon and ribavirin treatment for hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2011 , 17, 419-32	5.6	43
201	IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4892-7	5.6	16
200	IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 290-8	5.6	23
199	Sofosbuvir and ABT-450: terminator of hepatitis C virus?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3199-206	5.6	19
198	HLA class II associated with outcomes of hepatitis B and C infections. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5395-401	5.6	20
197	Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7055-61	5.6	6
196	Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7399-404	5.6	5
195	Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7852-66	5.6	7
194	Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8924-8	5.6	17
193	Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8940-8	5.6	29
192	Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8963-73	5.6	31
191	Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1359-71	5.6	17
190	Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2839-53	5.6	8
189	Chronic hepatitis C genotype 1 virus: who should wait for treatment?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2867-75	5.6	6

188	Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9245-52	5.6	7
187	Epidemiology and natural history of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9270-80	5.6	105
186	Interleukin 28B genetic polymorphism and hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12026-30	5.6	6
185	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , 2014 , 20, 13146-52	5.6	19
184	New treatments for chronic hepatitis C: an overview for paediatricians. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15965-74	5.6	13
183	Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17830-8	5.6	8
182	Interferon-Related genes and therapeutic response in Chinese hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4006-13	5.6	2
181	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4696-706	5.6	4
180	Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6800-16	5.6	27
179	Prevalence of rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2017 , 23, 3815-3824	5.6	9
178	(-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon- β production and inhibits hepatitis C virus replication in hepatocytes. <i>World Journal of Gastroenterology</i> , 2017 , 23, 5895-5903	5.6	3
177	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8120-8127	5.6	6
176	Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1478-1485	5.6	5
175	Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran. 2016 , 5, 90		1
174	The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin. <i>Journal of Research in Medical Sciences</i> , 2019 , 24, 12	1.6	0
173	Association between Hepatitis C Virus Viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) Genotype in Saudi Kidney Transplant Recipients. 2020 , 8, 46-52		2
172	IL28B SNPs rs12979860 and rs8099917 Are Associated with Inflammatory Response in Argentine Chronic HCV Patients. 2018 , 09, 79-91		4
171	Clinical characteristics of null responders to Peg-IFN β 2b/ribavirin therapy for chronic hepatitis C. 2010 , 2, 401-5		5

170	IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. 2013 , 5, 635-41	2
169	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. 2014 , 6, 759-65	3
168	Predictive factors associated with hepatitis C antiviral therapy response. 2015 , 7, 1617-31	58
167	Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. 2015 , 7, 2681-7	10
166	Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. 2015 , 7, 1125-32	7
165	Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. 2017 , 9, 677-688	7
164	Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. 2017 , 9, 1064-1072	8
163	Prevention of hepatitis C recurrence after liver transplantation: An update. 2012 , 3, 36-48	3
162	Association of ITPA polymorphism with outcomes of peginterferon- α plus ribavirin combination therapy. 2013 , 4, 54-60	5
161	Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. 2012 , 6, 98-106	21
160	Prediction of a null response to pegylated interferon α -2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. 2014 , 8, 421-7	2
159	Association between ITPA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. 2015 , 9, 214-23	4
158	Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α -2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus. 2017 , 11, 551-558	2
157	Role of IL28B genotype in older hepatitis C virus-infected patients. 2013 , 3, 54	3
156	New biomarkers for clinical management of hepatitis C virus infected patients. 2015 , 5, 59	1
155	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. 2015 , 4, 178-84	3
154	Analysis of the relationship between single nucleotide polymorphism of the CD209, IL-10, IL-28 and CCR5 D32 genes with the human predisposition to developing tick-borne encephalitis. 2017 , 71, 788-796	2
153	The IFN- α Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. <i>Hepatitis Monthly</i> , 2014 , 14, e15076	1.8 7

152	Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. <i>Hepatitis Monthly</i> , 2014 , 14, e15895	1.8	10
151	Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. <i>Hepatitis Monthly</i> , 2014 , 14, e17028	1.8	6
150	The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. <i>Hepatitis Monthly</i> , 2014 , 14, e18793	1.8	8
149	Interferon- λ Genetic Variations and Hepatitis C: Yet to be Discovered. <i>Hepatitis Monthly</i> , 2014 , 14, e19433	1.8	3
148	The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. <i>Hepatitis Monthly</i> , 2016 , 16, e34266	1.8	12
147	The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFN α -2a/RBV Combination Therapy in Azerbaijani Patients. <i>Hepatitis Monthly</i> , 2016 , 16, e35597	1.8	2
146	The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2016 , 16, e37011	1.8	7
145	Association of Genotype and Haplotype of IL-28B Gene with Hepatitis C Infection Outcome in Iran: Spontaneous Clearance Versus Chronic Infection. <i>Hepatitis Monthly</i> , 2017 , 17,	1.8	4
144	Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. <i>Hepatitis Monthly</i> , 2012 , 12, 77-84	1.8	8
143	The Impact of Host Factors on Management of Hepatitis C Virus. <i>Hepatitis Monthly</i> , 2012 , 12, 235-241	1.8	1
142	The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection. <i>Jundishapur Journal of Microbiology</i> , 2016 , 9,	1.2	1
141	IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2011 , 11, 958-959	1.8	9
140	The Correlation of IL28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2011 , 11, 975-9	1.8	17
139	Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B. 2013 , 68, 1325-32		4
138	IFN- λ ;3 (IL28B) genotyping by restriction fragment length polymorphism method: detection polymorphism of rs12979860. 2011 , 27, 231-234		5
137	Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 5515-9	1.7	6
136	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. 2019 , 8,		17
135	Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. 2019 , 8,		9

- 134 Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. **2014**, 28, 476-83 3
- 133 The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. **2016**, 4, e2576 5
- 132 Association between genetic polymorphisms of the gene and leukomonocyte in Chinese hepatitis B virus-infected individuals. **2017**, 5, e4149 4
- 131 Chronic Hepatitis C. **2022**, 163-201
- 130 Hepatologie (I). **2010**, 500-546
- 129 Innate Signatures of Immune Mediated Resolution and Persistence of Hepatitis C Virus Infections. **2011**, 127-140
- 128 Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load: Results of multicenter trial in Tohoku area of Japan. **2011**, 52, 652-661
- 127 Ischemic colitis induced on the injection day of pegylated-interferon for persistently normal ALT. **2011**, 52, 765-769 1
- 126 Hepatitis C Virus. **2011**, 1437-1455 1
- 125 [Genome-wide association study on and the clinical application to chronic hepatitis C]. **2011**, 61, 15-24
- 124 Double filtration plasmapheresis and peginterferon plus ribavirin combination therapy for chronic hepatitis C patients with genotype 1b and high viral load not cured by previous interferon therapy. **2011**, 52, 575-583
- 123 [Genetic polymorphisms as predictors of response to antiviral treatment in chronic hepatitis C virus infection]. **2011**, 152, 876-81
- 122 Immunopathogenesis of Liver Injury. **2012**, 55-65
- 121 Immune Control of HCV Infection. **2012**, 21-36
- 120 Mutations and the Development of Anti-viral Resistance. **2012**, 227-249
- 119 The Genetics of Virologic Response. **2012**, 183-192
- 118 Treating Chronic HCV Without Interferon and/or Ribavirin. **2012**, 261-269
- 117 Chronic HCV and HIV Coinfection. **2012**, 75-91

- 116 Treatment with Interferon and Ribavirin. **2012**, 115-130
- 115 Immune Modulators and Other Agents. **2012**, 131-148
- 114 Hepatitis C Genotype 4 Therapy: Progress and Challenges. 113-126
- 113 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients. 74-83
- 112 Mechanisms of Action of Antiviral Drugs: The Interferons. 25-35
- 111 New Horizons: IL28, Direct-Acting Antiviral Therapy for HCV. 196-213
- 110 HCV and Racial Differences. 185-189
- 109 Pharmacogenomics: Tailoring Treatment Based on Genotype. **2012**, 37-50
- 108 The relationship between the core protein polymorphism and the development of hepatocellular carcinoma in patients chronically infected with hepatitis C virus genotype 1b. **2012**, 53, 541-548
- 107 Response-guided therapy based on reaction to the initial dose using administration of peginterferon α -2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads. **2012**, 53, 18-27
- 106 Telaprevir in combination with peginterferon alfa-2b and ribavirin therapy for genotype 1 Japanese chronic HCV patients: Impact on adherence and antiviral effects. **2012**, 53, 69-77
- 105 Three cases of chronic hepatitis B in that interferon therapy was indicated. **2012**, 53, 853-861
- 104 Immune Pathogenesis of Viral Hepatitis B and C. **2012**, 111-128 1
- 103 Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. *World Journal of Gastroenterology*, **2012**, 18, 6481-8; discussion p. 6487 5.6 1
- 102 Two cases of acute hepatitis type C that improved with multidisciplinary therapy and interferon. **2012**, 53, 101-108
- 101 Pharmacogenomics and Personalized Medicine. *Nihon Ika Daigaku Igakkai Zasshi*, **2012**, 8, 9-17 0
- 100 Sustained virological response against hepatitis C virus in a patient with Down's syndrome treated with interferon- α **2012**, 53, 201-205
- 99 Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. *Hepatitis Monthly*, **2012**, 12, 190-195 1.8 21

98 Gene polymorphisms in chronic C virus hepatitis. **2012**, 4, 69-73

97 Prevention of Cancers Due to Infection. **2013**, 65-83

96 Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. **2013**, 54, 731-740

95 Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2. *World Journal of Gastroenterology*, **2013**, 19, 5754-8 5.6

94 A case of acute hepatitis C with hepatitis C virus (HCV) genotype 3a -discussion of IL28-B-. **2013**, 54, 120-127 1

93 Efficacy and safety of pegylated interferon^α-2a plus ribavirin treatment in refractory chronic hepatitis C patients -a multi-center study in Kyushu-. **2013**, 54, 266-276

92 Future directions in hepatitis C therapy. **2013**, 98-111

91 Hepatitis C Virus Testing. **2014**, 57-80

90 Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea. **2013**, 7, 585-93

89 Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. **2013**, 1, 39-44 3

88 Hepatitis C Virus: Pathogenesis and Host Immune Response. **2014**, 51-86

87 The roles of interferon regulatory factors in pancreatic diseases. **2014**, 29, 23-31 1

86 Discovery and Characterization of Cancer Genetic Susceptibility Alleles. **2014**, 309-321.e3

85 Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3. **2014**, 05, 111-117

84 Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response. **2014**, 60, 568-575

83 Treatment of chronic hepatitis C recent development and future perspective. **2014**, 55, 8-14 2

82 Role of interleukin-28B genetic polymorphisms in Korean patients with hepatitis C virus infection. **2014**, 8, 70-8 5

81 Developments in the treatment of hepatitis C virus infection. **2014**, 135-144

- 80 THE ROLE OF CYTOKINE GENES POLYMORPHISM IN HEPATITIS C VIRUS INFECTION. **2014**, 2, 687 2
- 79 IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. **2014**, 9, e112613
- 78 Interferon- β polymorphisms in pegylated-interferon- α plus ribavirin therapy for genotype-2 chronic hepatitis C. *World Journal of Gastroenterology*, **2015**, 21, 3904-11 5.6
- 77 Human Genetics and Infection. **2015**, 116-124.e3
- 76 Hepatitis C Virus Infection. 1939-1957
- 75 Association of the Treatment Induced Clearance of Hepatitis C Virus Infection with the IL28B Gene Polymorphisms. **2015**, 1, 005-008
- 74 [Programs for Continuing Medical Education: A session; 1. New therapeutic strategies for hepatitis C by direct-acting antivirals (DAA)]. **2016**, 105, 424-8
- 73 Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. **2016**, 62, 20-5
- 72 Host Factor Pharmacogenetics for Treatment of Infectious Diseases. **2016**, 291-300
- 71 Hepatitis B and C Viruses. **2016**, 641-657
- 70 Innate Immune Recognition of Hepatitis C Virus. **2016**, 299-329
- 69 Association of IL28B Genotypes and Baseline Serum Interferon-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. **2016**, 10, 446-55 2
- 68 Genetic Variation in Interleukin-28B and Response to Peg-IFN α -2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection. *Jundishapur Journal of Microbiology*, **2016**, 10, 1.2
- 67 Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. **2016**, 4, 320-327 14
- 66 HCV Drug Resistance. **2017**, 579-609
- 65 Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research in Latin America). **2017**, 333-359
- 64 THE IMPACT OF THE POLYMORPHISM OF THE INTERLEUKIN-28 GENE ON THE COURSE OF THE CHRONIC EPSTEIN-BARR VIRUS INFECTION. **2017**, 13, 068
- 63 2) Hepatitis C. **2017**, 106, 428-432

62	The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection. 2017 , 1,		
61	[Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects]. 2017 , 89, 110-114		
60	FREQUENCY OF OCCURRENCE OF POLYMORPHIC VARIANTS OF IL28B GENE AND GENOTYPES OF HEPATITIS C VIRUS IN POPULATION OF YAKUTIA: CLINICAL OUTCOMES. 2017 , 86-92		1
59	Relationship between IL28b Gene Polymorphisms and the Risk of Hepatocellular Carcinoma Development within Vietnamese Hepatitis B Virus Carriers. <i>Journal of Clinical Microbiology and Biochemical Technology</i> , 035-039	0.7	1
58	Interleukin 28B Genetic Polymorphism and Spontaneous Recovery from Hepatitis B Virus Infection in an Iranian Azeri Population. <i>Hepatitis Monthly</i> , 2017 , 17,	1.8	0
57	The Role of Biochemical Variations and Genotype Testing in Determining the Virological Response of Patients Infected with Hepatitis C Virus. <i>Journal of Global Infectious Diseases</i> , 2018 , 10, 89-98	2.8	
56	Interferon lambda 4 impacts broadly on hepatitis C virus diversity.		
55	Kronik hepatit C tedavisine yanıt tahmin etmede IL28B gen polimorfizmi. <i>Pamukkale Medical Journal</i> ,		
54	Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes.		
53	Genetics of Infectious Diseases. 2019 , 145-174		
52	Hepatitis C Virus Infection. 2019 , 323-330		
51	Characterization of Peripheral Blood Mononuclear Cells Gene Expression Profiles of Pediatric Staphylococcus aureus Persistent and Non-Carriers Using a Targeted Assay.		
50	Advances in Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2019 , 15, 106-114		0
49	The Role of Autophagy in Interferon/Ribavirin Responders and Non-Responders with Hepatitis C Virus Infection. <i>Jundishapur Journal of Microbiology</i> , 2020 , 13,		1.2
48	Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan. <i>In Vivo</i> , 2020 , 34, 3309-3313		2.3
47	Hepatitis C. 2020 , 273-286		
46	Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. <i>Annals of Hepatology</i> , 2021 , 100577	3.1	0
45	IFN-λ may contribute to HCV persistence by increasing ER stress and enhancing IRF1 signaling.		

44	Advances in hepatology: current developments in the treatment of hepatitis and hepatobiliary disease. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 84-8	0.7	
43	IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 366-73	0.7	5
42	Genome-Wide Association Studies: "SNPing" Away at Liver Disease. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 407-9	0.7	
41	Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. <i>Hepatitis Monthly</i> , 2011 , 11, 163-72	1.8	26
40	Management of hepatitis C virus infection: the basics. <i>Topics in Antiviral Medicine</i> , 2012 , 20, 154-61	3.2	14
39	The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents. 2012 , 1, 33-39		2
38	Innate immunity: a new chapter for hepatitis C. <i>Annals of Gastroenterology</i> , 2012 , 25, 232-240	2.2	
37	Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. <i>Journal of Research in Medical Sciences</i> , 2014 , 19, 1062-7	1.6	4
36	Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. <i>Puerto Rico Health Sciences Journal</i> , 2014 , 33, 177-83	0.5	2
35	Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 7446-56		2
34	Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015 , 8, 278-87	1.2	6
33	Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 14871-84		
32	Genetic polymorphisms of Trim5a are associated with disease progression in acutely and chronically HIV-infected patients. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 16199-206		2
31	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. <i>Journal of Preventive Medicine and Hygiene</i> , 2013 , 54, 83-6	1.4	7
30	Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin. <i>Iranian Journal of Pathology</i> , 2016 , 11, 216-221	1.2	5
29	Interleukin-28B rs12979860 C/T Polymorphism and Acute Cellular Rejection after Liver Transplantation. <i>International Journal of Organ Transplantation Medicine</i> , 2017 , 8, 28-33	0.7	3
28	Highlights of the 2012 American Association for the Study of Liver Diseases meeting. <i>Topics in Antiviral Medicine</i> , 2012 , 20, 180-4	3.2	0
27	The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 2191-2197	1.7	

26	The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. <i>Microbial Pathogenesis</i> , 2021 , 162, 105311	3.8	0
25	Immunopharmaco-genomics: future of clinical medicine. 2022 , 347-384		
24	Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients. <i>Archives of Virology</i> , 2021 , 167, 153	2.6	0
23	Association between Maternal Non-Coding Interferon- β Polymorphisms and Congenital Zika Syndrome in a Cohort from Brazilian Northeast. <i>Viruses</i> , 2021 , 13,	6.2	0
22	The Impact of IFN β on the Adaptive Immune Response to SARS-CoV-2 Infection. <i>Journal of Interferon and Cytokine Research</i> , 2021 , 41, 407-414	3.5	0
21	ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS β AVAILABLE RESULTS AND FUTURE PROSPECTS. <i>Problemy Zdorov'ya i Ekologii</i> , 2017 , 31-35	0.2	1
20	Road to elimination of HCV: Clinical challenges in HCV management.. <i>Liver International</i> , 2021 ,	7.9	4
19	Risk of hepatocellular carcinoma after hepatitis C virus cure.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 96-107	5.6	4
18	The knowledge on HCV. <i>Infectious Microbes & Diseases</i> , 2022 , Publish Ahead of Print,	1.3	0
17	Features of Lipid Metabolism in HCV Infection. 2021 , 412-421		
16	Genetic Predisposition and the Variable Course of Infectious Diseases.. <i>Deutsches A&#x0308;rzteblatt International</i> , 2022 ,	2.5	0
15	From pharmacogenetics to pharmaco-omics: Milestones and future directions.. <i>Human Genetics and Genomics Advances</i> , 2022 , 3, 100100	0.8	1
14	The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection.. <i>Biomedical Reports</i> , 2022 , 16, 9	1.8	
13	Data_Sheet_1.pdf. 2019 ,		
12	genotype influences the rate of HIV-1 seroconversion in men who have sex with men.. <i>Virulence</i> , 2022 , 13, 757-763	4.7	
11	The role of IFNL4 in liver inflammation and progression of fibrosis.. <i>Genes and Immunity</i> , 2022 ,	4.4	1
10	STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon- α therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIFN- α therapy. <i>Journal of Medical Virology</i> ,	19.7	0
9	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5

- 8 The presence of interferon affects the progression of non-alcoholic fatty liver disease. *Genes and Immunity*, 4.4 ○
- 7 Favorable Genotypes of Type III Interferon Confer Risk of Dyslipidemia in the Population With Obesity. *Frontiers in Endocrinology*, 13, 5-7 ○
- 6 Hepatitis C: epidemiology, natural history, and diagnosis. **2023**, 229-250 ○
- 5 The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update. **2023**, 14, 405 ○
- 4 Genetic Susceptibility to Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection. **2023**, 15, 559 ○
- 3 Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies. **2023**, 13, ○
- 2 Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma. ○
- 1 Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2. **2023**, 57, 291-298 ○